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ABSTRACT 
Myocarditis is the inflammation of the cardiac muscle and a leading cause of 
sudden cardiac failure. Previously, our lab has shown that natural killer (NK) cells 
suppress group B coxsackievirus (CVB) and mouse cytomegalovirus (MCMV)-induced 
viral myocarditis severity by minimizing virus replication. We demonstrate that the 
protective capabilities of NK cells in myocarditis extend beyond controlling viral 
infection into directly controlling autoimmune-mediated inflammation. Experimental 
autoimmune myocarditis (EAM) is instigated in BALB/c mice by immunization with 
cardiac myosin peptide. NK cells accumulated in the heart through EAM, secreted IFNγ, 
perforin, and granzyme-B, and had upregulated levels of activation receptors compared to 
peripheral NK cells. Wildtype (WT) mice undergoing EAM showed significantly greater 
disease severity when NK cells were depleted using anti-asialo GM1 antibodies. This was 
accompanied by increased cardiac inflammation, collagen deposition, and a 10-fold 
increase in the proportion of infiltrating eosinophils. This increased influx of eosinophils 
was required for the effects of NK depletion in WT mice, indicating that NK cells control 
disease severity through the suppression of eosinophil infiltration. NK cells had the 
ability to control eosinophil-related chemokine expression from primary cardiac 
fibroblasts (CF) – levels of eotaxin 1 (CCL11), eotaxin 2 (CCL24), CXCL9, and 
CXCL10 were regulated by NK cells both in vivo and in vitro. Altogether, we show a new 
pathway of eosinophilic regulation through interactions with NK cells and open a new 
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CHAPTER I: INTRODUCTION TO MYOCARDITIS AND 
DILATED CARDIOMYOPATHY 
2 
Myocarditis: Definition and Diagnosis 
Myocarditis is the inflammation of the cardiac muscle1. Histopathologically, 
myocarditis is defined by the Dallas criteria to be the presence of inflammatory infiltrate 
associated with myocyte necrosis in the absence of ischemia2-4. Presence of 
cardiomyocytes necrosis with an inflammatory cellular infiltrate is characteristic for 
active myocarditis5. Several different subtypes of myocarditis exist depending on 
histological assessment. If there is inflammation in the absence of myocyte death, the 
disease is defined as borderline myocarditis. In the presence to necrosis, the major 
infiltrating cell-type will distinguish lymphocytic, giant cell, and eosinophilic 
myocarditis, though other cell types may also be present (Table 1)6.  
Histological determination of disease requires tissue obtained by endomyocardial 
biopsy (EMB) or post-mortem autopsy. Immunohistochemistry may further delineate 
inflammatory cell populations based on surface markers such as MHCII and CD37-9. 
EMB is widely used in Europe, but its use remains limited in the United States10,11 In the 
US, the view is that limited sampling results in EMB-based myocarditis diagnosis being 
prone to low sensitivity and difficulties in establishing a prognosis12. Perceived risks of 
patient endangerment, extensive costs, and limited accessibility to expert pathological 
interpretations underline the need for improved tools in the early diagnosis of 
myocarditis10. However, the European Society of Cardiology strongly supports EMB for 
all clinically suspected myocarditis patients. The complication rate is low and most 
importantly only EMB can confirm the myocarditis infection status, necessary for 
determining the patient treatment.   
Clinical symptoms of myocarditis may range from mild chest paints to cardiac 
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shock and ventricular arrhythmias12. Clinical myocarditis can be divided based on clinical 
and pathological criteria as fulminant, sub-acute, chronic active, and chronic persistent 
subtypes13,14. Fulminant myocarditis is defined as active myocarditis accompanied by 
acute, severe cardiac failure15. Immediate intervention may be necessary for cardiac 
survival16. If diagnosed quickly and treated aggressively, however, the large majority of 
fulminant myocarditis patients will make a full recovery. Non-fulminant cases, despite 
not requiring immediate intervention, appear to have decreased long-term survival17.  
Several methods have been undertaken to improve diagnosis of myocarditis in a 
non-invasive manner. Studies have examined markers of cardiac injury, such as cardiac 
troponin I (cTnI)18, myosin or cTnI antibodies19,20, and creatine-kinase MB21, but these 
signs do not distinguish between different causes of cardiac myocyte injury and do not 
alone improve the determination of future therapy22,23.  
Echocardiography, a first-line tool in the identification of cardiac abnormalities, is 
of limited use in the positive diagnosis of myocarditis. Myocarditis patients do not 
display any specific echocardiographic characteristics. While some parameters such as 
segmental wall abnormalities, LV wall thickness or ventricular thrombi showed some 
association with myocarditis, they are indistinguishable from other cardiac conditions 
such as myocardial infarction24. Echocardiography is an excellent method for ruling out 
other causes of heart failure and to monitor patient progress, but cannot be relied on a 
sole diagnostic tool15,25,26. 
Electrocardiograms (EKG) may also be problematic in the positive diagnosis 
myocarditis25,27. Acute myocarditis patients may display non-specific ST-segment and T-
wave abnormalities or present with elevated ST-segments that directly mirror an acute 
4 
myocardial infarction28,29. In one study of 42 histologically proven myocarditis patients, 
58% had normal P-waves, 49% had normal QRS-complexes, and 64.5% had no 
repolarization abnormalities. In summary, the predictive value of EKG was low, although 
all myocarditis patients displayed at least abnormality among the parameters measured. 
Of these, abnormal QRS complexes and left bundle branch block (LBBB) were most 
strongly correlated with poor clinical outcomes30.  
Cardiac magnetic resonance imaging (MRI) has shown great promise among non-
invasive techniques being used for diagnosis of acute myocarditis, especially in the 
earliest stages of disease4,31. T2-weighted images may show the presence of 
inflammation-associated edema in the myocardial tissue32. Myocardial global relative 
enhancement (gRE) studies to examine myocardial hyperemia and increased capillary 
permeability have sensitivities between 63-85%33. Furthermore, the use of cardiac MRI-
guided EMB to facilitate sampling of the abnormal regions of the LV is a powerful tool in 
improving the diagnosis of myocarditis34.  
In conclusion, EMB remains the gold standard for myocarditis diagnosis. While 
the inclusion of multiple non-invasive tests such as serum inflammatory markers and 
cardiac MRI do not replace EMB, they serve as complement during the diagnostic 
process of myocarditis and subsequent patient monitoring.  
Myocarditis Etiology 
Multiple agents are associated with the induction of clinical myocarditis (Table 
2)35. However, in most cases, no specific toxic agent or active pathogen can be 
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identified36. The causative event may have occurred well before the onset of clinical 
symptoms, leaving no trace in the patient. Difficulties in determining the etiology of 
myocarditis results in a large majority of cases being identified as idiopathic12.  
Viruses are the most commonly identified causes of myocarditis37. Parvovirus 
B19 is the most commonly isolated viral pathogen in Europe, a recent shift from group B 
coxsackievirus (CVB) and adenovirus9,38. Studies done with hepatitis C found strong 
correlations between HCV antibodies and RNA in proven myocarditis patients39. Other 
associated viral pathogens include HIV, Epstein-Barr virus, cytomegalovirus (CMV), and 
herpesvirus40. There is, however, little evidence for an association between levels of virus 
and clinical severity of myocarditis41-44.  
There is also increasing recognition of the myocarditis brought on by infection 
with Trypanosoma cruzi, a growing public health concern as the disease spreads north 
from Central and South America. Infection with T. cruzi results in Chagas disease. This 
flagellated parasite enters the bloodstream through the fecal matter of their vector, the 
triatomine bug. Upon scratching at the bite site, the fecal matter is smeared into the 
broken skin and the flagellates invade their new host45. While the course of disease is 
unpredictable, the acute phase is associated with transient, febrile myocarditis. 
Etiologically, it is thought to be associated with cross-reactions of the immune system 
between T. cruzi proteins and cardiac muscle46. Afterwards, 30% of patients will 
gradually develop severe chronic myocarditis despite a scarcity of parasites found in the 
heart47. Largely found in South America, cases and infected vectors have been found in 
the southern United States and there have been several reports of infection through 
transfusions from imported blood48,49.  
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Hypersensitivity reactions to drugs also constitute a significant percentage of 
myocarditis patients50,51. The list of drugs associated with myocarditis vary greatly, with 
Table 2 providing a limited list, and can occur in patients where they were previously 
well-tolerated52. Often, this hypersensitivity reaction responds to the withdrawal of the 
offending drug agent and the application of corticosteroids52-54.   
Autoimmune mechanisms may play a role in the development of myocarditis. 
Viral invasion in the heart results acute cardiac damage and the release of multiple self-
antigens into an inflammatory environment43. Also, individuals with well-established 
autoimmune disorders such as systemic lupus erythematosus (SLE), hyper IgE (Job’s) 
syndrome, celiac disease, and multiple sclerosis can present with secondary 
myocarditis55-58. 41-56% of myocarditis patients produce autoantibodies against cardiac 
proteins, most commonly against cardiac myosin heavy chain, and additional proteins 
such as cTnI and skeletal myosin may also be targeted35,59,60. These cardiac 
autoantibodies are correlated with reduced LV function in chronic myocarditis, though 
whether they are directly responsible is unknown61,62. Additionally, CD4+ cells in the 
blood of myocarditis patients proliferate upon stimulation with cardiac myosin in vitro, 
suggesting the development of an anti-cardiac humoral immune response63.  
Myocarditis: Treatment 
Management of clinical myocarditis is dependent on the patient presentation, 
suspected etiology, and disease stage. In cases of fulminant myocarditis presentation with 
cardiac shock and severe ventricular dysfunction, patients should first be managed in 
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intensive care units with hemodynamic monitoring35. Some cases may require ventricular 
assist devices or extracorporeal membrane oxygenation (ECMO)64,65. In stable patients 
and those presenting with non-fulminant myocarditis, combination treatments are given, 
aimed at decreasing cardiac load and improving function in order to limit chances of a 
cardiopulmonary event. Suggested treatments include diuretics, to common to prevent 
fluid overload and angiotensin-converting enzyme (ACE) inhibitors, which may limit 
maladaptive chronic remodeling if treatment is begun in the early stages of disease 
regardless of etiology5,35,66,67.  
Additionally, the use of beta-blockers results in increased ventricular function and 
better clinical outcomes in non-fulminant myocarditis4,35,68,69. Despite this treatment and 
the recommended avoidance of exercise, patients may continue to develop persistent 
heart failure where treatments with aldosterone antagonists may be of benefit. Their 
mechanism of action is not well-defined, but may reduce cardiac remodeling through the 
suppression of fibrosis. These drugs resulted in a reduction of hospital admissions and 
increased survival in heart failure patients5,35,66,67.  
Current recommended therapies are aimed only at improving cardiac function as 
there are no effective specific treatments for myocarditis. The use of interferon-beta 
(IFN-β) to treat viral myocarditis in some studies resulted in the elimination or reduction 
of viral presence from the heart, the improvement in cardiac function, and an improved 
10 year survival35,70. Interferon-alpha 2 (IFN-α2) in animal models of viral myocarditis 
resulted in the removal of viral genome in the heart and decreased cardiac inflammation 
and injury71.  
Immunoadsorption (IA) to remove circulating IgG antibodies and intravenous 
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immunoglobulin treatment (IVIG) have both been utilized in clinical trials. The latter was 
associated with improved LV function in heart failure trials, but has not been tried in 
studies of histologically proven myocarditis72,73. IA, aimed at limiting autoantibody 
levels, has been shown to decrease myocardial inflammation, though this also was not 
done in for histologically proven myocarditis patients74.  
Direct immunosuppression using steroids alone or in combination with 
azathioprine or cyclosporine has been a target of clinical trials.  In RNA virus-negative 
and autoantibody-positive patients with EMB-positive myocarditis, treatment with 
prednisone and azathioprine improved LV function and decreased LV diastolic 
dimensions75. Other trials, however, that treated patients with unknown etiology did not 
show improvement when immunosuppressive strategies were added to symptomatic 
treatment plans35,59,60.   
Approximately half of acute myocarditis patients will resolve within the first 
month of disease. In the remaining patients, 25-50% will experience deteriorating cardiac 
function despite being monitored and treated. Within this population, a secondary 
phenotype emerges known as inflammatory dilated cardiomyopathy (DCMI), described 
in the next section.  
 
Dilated Cardiomyopathy (DCM) 
Cardiomyopathies are a large and heterogeneous group of disorders associated 
with the morphologically abnormal appearance and failure of myocardial performance76. 
DCM is classified as a type of cardiomyopathy characterized by ventricular chamber 
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enlargement in the absence of hypertension or other abnormal loading conditions. 
Physiologically, patients may present with reduced cardiac function as seen by decreased 
ejection fraction due increased end-diastolic dimensions. 
The age-adjusted prevalence of DCM in the United States is approximately 36 
cases per 100,000 individuals76. DCM is the third most common cause of heart failure 
and the most common form of cardiomyopathy. 40% of DCM cases are believed to be 
genetic in nature, meaning that the disease has occurred at least two closely related 
family members77,78. Around 30 genes have been identified as associated with the disease, 
though most familial cases are heterogeneous with private gene abnormalities78. It has 
been estimated that over 90% of familial cases have been inherited in an autosomal 
dominant manner and show age-dependent penetrance along with variable expression77.  
Guideline-directed medical therapy (GDMT), as approved by the American Heart 
Association (AHA) and the American College of Cardiology Foundation (ACCF), for 
DCM is first aimed at reducing pressure overload by limiting hypertension through the 
use of diuretics, beta-blockers, and angiotensin-targeting drugs such as ACE inhibitors or 
angiotensin II receptor blockers (ARBs). Patients are also recommended several 
behavioral changes including sodium limitation.  
25% of patients with recent onset of symptomatic DCM will rapidly improve even 
in the absence of correct GDMT. However, after 3 months of no improvements is 
associated with poor prognosis long-term. Some patients benefit from a left ventricular 
assist device (LVAD) and an implantable prophylactic fibrillator (IPD), but heart 
transplant remains the only curative treatment for end-stage DCM79,80. DCM patients 
constitute the majority of heart transplants in the United States, with DCM following 
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myocarditis making up 9% of all DCM-related heart transplants15.  
Outcomes of DCM-related heart transplants are significantly worse among those 
from a primary diagnosis of myocarditis. In one study by Pietra et al, of the 231 children 
awaiting cardiac transplant, 80% received transplants during the study period with 86% 
being UNOS Status 1. The 1, 5, and 10 year survival rates were 92%, 80%, and 72%, 
respectively. The strongest indicators for negative clinical outcomes were a primary 
diagnosis of myocarditis, older age at transplantation, and lower LV end diastolic 
dimensions (LVEDD). Survival of myocarditis-based DCM patients, which were 11% of 
the total transplants, were 83% at 1 year and 65% at 3 years, significantly lower than non-
stratified survival rates69.  
The poor clinical outcomes associated with myocarditis-based DCM raises the 
possibility that the etiological agent of myocarditis, whether viral or autoimmune, may 
persist after transplantation. This underscores the need for a specific and curative therapy 
for myocarditis in both chronic patients and those apparently resolved cases under going 
cardiac transplantation due to secondary DCM.  
DCM may be primary or acquired. Primary DCM is considered genetic or familial 
in nature, whereas secondary DCM is associated with of an inflammatory or autoimmune 
disorder81. Secondary DCM is also known as inflammatory DCM (DCMI), if dilation was 
a result of proven cardiac inflammation or inflammation is still present in the cardiac 
tissue. In myocarditis-based DCMI, the inflammatory infiltrate and subsequent tissue 
damage begins a wound-healing cascade of events that ultimately leads to significant 
interstitial edema, myocyte necrosis, and replacement fibrosis and collagen deposition. In 
some cases, underlying low levels of viral pathogen may result in continual cardiac 
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myocyte damage and inflammation82,83. It has been postulated that the continual cardiac 
myocyte injury and subsequent fibrosis is driven by an autoimmune response against 
myocyte-associated proteins60. 
Myocarditis and DCM: Animal Models 
Animal models of myocarditis and DCM are necessary in order to better study the 
natural history of the disease. There are several accepted models of murine myocarditis. 
Viral myocarditis can be induced in susceptible mouse strains with CVB or murine 
cytomegalovirus (MCMV) (Figure 1). Following infection, mice develop a primary 
disseminated viral infection by day 4, but in surviving mice a secondary and tertiary 
phase disease progress occurs84-87. 
Inoculation of mice with CVB, similar to MCMV, can induce a fatal acute viral 
myocarditis within the first week of disease with substantial damage to the 
cardiomyocytes and disseminated viral presence. However, the Nancy strain of CBV may 
be heart-passaged first in order to induce a milder disease more conductive to survival 
and progression to the secondary and tertiary stages84. In the surviving mice, an acute 
cardiac inflammatory stage occurs from day 7 and resolves by day 14 coinciding with the 
peak of infiltration. After day 14, the disease resolves with a tertiary chronic low-grade 
inflammation following day 28 onwards in susceptible mouse strains such as BALB/c or 
A/J. This low grade inflammation coincides with the development of DCMI. However, 
the genetic resistance to the inflammatory phase in C57B/6 and B10 strains can be 
reduced by administration of bacterial lipopolysaccharide (LPS), interleukin (IL) 1β or 
tumor necrosis factor alpha (TNF-α)85,87.  
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Active virus can be isolated from the heart only up to day 10 of infection, with 
detectable RNA being found until day 1485,88. Hence, the chronic phase of murine viral 
myocarditis is thought to be largely autoimmune-driven in nature, and suggests the 
possibility of the virus acting as an adjuvant. In both viral models, titers of anti-myosin 
IgG and IgM can be found in resistant and susceptible mice strains89,90. Furthermore, the 
antibodies found in susceptible strains are specific for cardiac myosin and are not cross-
reactive with other forms of myosin90. Other autoantibodies found include troponin I, 
tropomyosin, and adenine nucleotide translocator (ANT)91 It is been shown that viral 
replication in the heart itself is needed to cause myocardial injury. The depletion or 
absence of either the CD4+ or CD8+ T-cell component results in a significant reduction of 
the subsequent post-viral myocarditis92,93. Taken together, it is likely the viral-mediated 
damage of the heart begins an immune cascade resulting in the development of anti-
cardiac adaptive immunity. 
Myocarditis can also be induced in the absence of an active pathogen. 
Experimental autoimmune myocarditis (EAM) is evoked by immunization of susceptible 
mouse strains, which are identical to the mouse strains susceptible to viral myocarditis. 
Mice are subcutaneously (s.c.) injected with 100ug of either whole cardiac myosin or a 
strain-specific myocarditogenic peptide fragment derived from α-myosin heavy chain 
(Table 3) emulsified in complete Freund's adjuvant (CFA) at day 0 and day 7 of disease, 
along with 500ng of pertussis toxin intraperitoneally (i.p.) to further stimulate the 
immune system61,84,94. The different peptides used to induced EAM in various strains 
indicates that different epitopes of cardiac myosin are targeted by the immune system, as 
strains are generally not reactive to other peptides. A/J mice immunized with cardiac 
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troponin I instead of cardiac myosin develop similar disease95. Importantly, EAM mimics 
the clinical myocarditis-based progression to a secondary disease phase, DCMI, in nearly 
all mice immunized.  
EAM is marked by a priming phase from day 0 to 10, where cardiac infiltrate is 
not evident yet, but immune responses are being initiated as shown by the rise in cardiac 
myosin-specific antibodies. Following day 10, CD45+ inflammatory cells begin 
infiltrating the cardiac space and peaks at day 21. This stage of disease mimics that of the 
secondary phase of CVB-induced myocarditis and is accompanied by anti-cardiac myosin 
antibodies and T-cells. Infiltration begins to resolve by day 35. The animal develops 
DCMI by day 45 as the inflammation is replaced by the deposition of collagen and other 
fibrotic mediators likely due to wound healing processes (Figure 2). EAM allows for the 
separation of the subsequent antigen-specific adaptive immune response independent of 











Figures and Tables 
Table 1. Common Myocarditis Subtypes and Characteristics4,6,96 
Subtype Myocyte 
Necrosis?
Diagnostic infiltrate Secondary infiltrate 
Lymphocytic Y Lymphocytes Plasma cells, neutrophils, 
macrophages 
Giant cell Y Giant cells Lymphocytes, eosinophils 
Eosinophilic Y Eosinophils Lymphocytes
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Table 2. Common etiologies of myocarditis4,6,37,39,96 
Infectious Immune-mediated Toxin-mediated 
Viral Autoimmune Ethanol 
Adenovirus Celiac disease Arsenic 
Coxsackievirus  Churg-Strauss syndrome Copper 
Cytomegalovirus Hypereosinophilic syndrome Thyreotoxicosis 
HIV Inflammatory bowel disease  
Parvovirus  Kawasaki disease  
 Systemic lupus erythematosus  
Bacterial   
Streptococcus Hypersensitivity reactions  
Mycobacterium Penicillin  
Legionella Tetracyclines  
 Benzodiazepines  
Protozoan   
Trypanosoma cruzi   















Table 3. Susceptible strains of mice and their associated peptides in experimental 
autoimmune myocarditis84,94 
Antigen Strain 1° Amino Acid Sequence 
cardiac myosin all  
MyHCα334-352 A/J, C3H (H2k) DSAFDVLSFTAEEKAGVYK 
MyHCα614-629 BALB/c (H2d) Ac-SLKLMATLFSTVASAD 
MyHCα406-425 SWXJ (H2s) KVGNEYVTKGQSVQQVYYSI 
MyHCα1631-1650 SWXJ (H2s) LSQANRIASEAQKHLKNSQA 
cardiac troponin I A/J, BALB/c  

















Figure 1. Natural History of Heart-Passaged CVB-Myocarditis85,86 
Heart-passaged coxsackievirus B (CVB) (Nancy strain) evokes myocarditis in BALB/c 
mice. Inoculated mice develop a disseminated viral infection for the first seven days until 
the virus invades cardiac tissue, where viral titer will peak around the same time as the 
ensuing cardiac inflammation. This coincides with anti-cardiac myosin IgG titers in the 
serum of infected mice. Inflammation will subside by day 28 of infection, where the mice 
develop a moderate chronic inflammation. The development of inflammatory dilated 
cardiomyopathy (DCMI) begins around day 35.  
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Figure 2. Progression of experimental autoimmune myocarditis84,94 
Experimental autoimmune myocarditis (EAM) is instigated when susceptible strains of 
mice are immunized with cardiac myosin alpha heavy chain protein or peptide emulsified 
in complete Freund’s adjuvant (CFA) on days 0 and 7 of EAM. Mice undergo a priming 
phase from days 0-7, followed the beginnings of cardiac inflammation which peaks at 



























WT BALB/c, Rag1-/-, C.Cg-Gata1tm6Sho/J, IFNγ-/-, IFNγR1-/-, and CCR3-/- mice were 
purchased from the Jackson Laboratory and were bred and maintained in the 
conventional housing facilities at The Johns Hopkins University School of Medicine 
(Baltimore, Maryland). All protocols have been reviewed and approved by the Johns 
Hopkins Animal Care and Use Committee. 
Immunization with MHC614-629
Male 6-8 week old BALB/c mice were subcutaneously injected with 100µg of 
myocarditogenic peptide of cardiac myosin heavy chain (MyHC) MyHC614-629, 
emulsified in an equal volume of complete Freund’s adjuvant (CFA) (Sigma Aldrich, St. 
Louis, Missouri), supplemented with 4mg/ml of H37Ra tuberculosis extract (Difco, 
Lawrence, Kansas) on days 0 and 7 for a total volume of 100uL per injection94. 500ng of 
Pertussis toxin in 100µl of PBS (Sigma Aldrich, St. Louis, Missouri) was administrated 
intraperitoneally (i.p.) on day 0. 
Assessment of EAM 
Mice were sacrificed on day 14 or day 21 as required. Hearts were perfused with 1X 
phosphate buffered saline (PBS) for 3 minutes, removed and fixed. Longitudinal sections 
through the left ventricle were stained with hematoxylin and eosin (H&E)140,141,231,256. 
The degree of myocardial infiltration and fibrosis was determined blindly by at least two 
individuals by microscopy. Histology scored based on percentage of infiltrated tissue as 
follows: 0 = no infiltration, 1 = ≤10%, 2 = 10-30%, 3 = 30-50%, 4 = 50-90%, 5 ≥90%94. 
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Assessment of collagen deposition 
Hearts at day 21 of EAM were perfused with 1X PBS as in for the assessment of EAM. 
Cardiac sections were stained with Masson Trichome140,141,231,256. Images of whole 
cardiac sections were uploaded to ImageJ software (National Institutes of Health, 
Bethesda, Maryland) and using the loupe tool, the left ventricle was selected. Blue and 
red pixels within the selected area were enumerated and the degree of fibrosis represented 
as a percentage of blue pixels from the total number of pixels (red and blue).  
Echocardiography 
An Acuson Sequoia 256 high-resolution microimaging system with a 13 MHz transducer 
was used (Visualsonic, Toronto, Ontario, Canada). Any fur on the abdominal surface of 
the mice was removed using a depilatory cream, Nair (Church and Dwight, New Jersey, 
USA) 24 hours prior to imaging. In conscious mice, the heart was imaged in the 2D mode 
in the parasternal short-axis view. From the M-mode, the left ventricular wall thickness 
and chamber dimensions were measured. The M-mode cursor was positioned 
perpendicular to the interventricular septum (IVS) and the left ventricular posterior wall 
(LVPW) with three to five readings taken for each measurement. The left ventricular end 
diastolic dimension (LVEDd), end systolic dimension (LVEDs) and the interventricular 
septal wall thickness at end diastole (IVSD) were measured from a frozen M-mode 




Intracardiac and splenic flow cytometry  
To create a cardiac single-cell suspension, the aorta was cannulated with a 23-gauge 
needle to perfuse hearts with 15mL of cold 1x PBS for 3 minutes to remove blood. To 
create cardiac single-cell suspensions, hearts were bisected, placed in C-tubes, and 
dissociated on the GentleMACS system (Miltenyi Biotech, Bergisch Gladbach, 
Germany) under program heart_01. Cells were shaken with 10mg of collagenase II and 
1.5mg of DNase I (Worthington Biochemical, Lakewood, New Jersey) for 30 minutes at 
37C. Cells were dissociated again under program heart _02 and rinsed twice with 1x PBS 
with 0.05% bovine serum albumin (BSA) (Sigma-Aldrich, Saint Louis, Missouri) and 
2mM ethylenediamine tetraacetic acid (EDTA) (Corning Cellgro, Corning, New York).  
To create a splenic single-cell suspension, spleens were dissociated between two frosted 
glass slides and incubated with 2mL of ammonium-chloride-potassium (ACK) Lysing 
Buffer for 1 minute to remove red blood cells. The remaining cells were rinsed with 1x 
PBS and filtered through a 40uM mesh. 1-3x106 cells were incubated with 1uL of 
LIVE/DEAD Aqua (Invitrogen, Carlsbad, California) for 30 minutes in 1x PBS to stain 
dead cells. Cells were then incubated with 2 µg of αCD16/32 at 4°C for 10 minutes prior 
to the addition of fluorescent antibodies (CD3, CD4, CD8, CD45, Ly6G, SiglecF, NKp46, 
DX5, CD11b, CD11c, and F4/80) (eBioscience, San Diego, California) to prevent non-
specific binding of fluorescent antibodies. Samples were incubated with fluoresecent 
antibodies at 4°C for 10-20 minutes, washed in 1ml of 0.05% BSA and 2mM EDTA in 1x 
PBS and fixed in fixation and permeabilization buffer (BD Bioscience, Franklin Lakes, 
New Jersey) for 30 minutes.  
For intracellular cytokine staining, suspensions were first incubated prior to staining for 
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4-6 hours with 20ng/mL PMA, 1ug/mL ionomycin, and Golgistop (BD Bioscience, 
Franklin Lakes, New Jersey) in complete Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Corning Cellgro, Corning, New York). Cells were surface stained and then 
permeabilized with 1x permeabilization buffer (BD Bioscience, Franklin Lakes, New 
Jersey) overnight at 4°C. Cells were then incubated with anti-cytokine antibodies 
(eBioscience, San Diego, California) for 30 minutes at 4°C. Cells were washed in 1x 
permeabilization buffer and resuspended in 100-200µl of buffer.  
Samples were acquired on the LSR II quad-laser cytometer running FACSDiva 6 (BD 
Immunocytometry, Franklin Lakes, New Jersey). Data were analyzed with FlowJo 7.6 
(Treestar Software, Ashland, Oregon). 
 
Depletion of NK cells with anti-asialo GM1 antibody 
To deplete NK cells prior to immunization, 6 week old male BALB/c mice were injected 
intraperitoneally (i.p.) with 1mg of anti-asialo GM1 in 200uL of sterile 1x PBS (Wako 
Chemicals USA, Richmond, Virginia) antibody everyday six days prior to the first 
immunization (days -6 to day 0)128,257. To maintain decreased levels of NK cells after the 
first immunization (day 0), 1mg of anti-asialo GM1 antibody was administered every 
other day from day 1 until day 21 or sacrifice. Control mice received 1mg of rabbit IgG 
in 200uL of sterile PBS or 200uL of PBS alone (Sigma Aldrich, Saint Louis, Missouri) by 
the same schedule. 
 
Isolation of primary adult mouse cardiac fibroblasts  
Hearts dissected from 6-8 week old naïve BALB/c mice were perfused through the aorta 
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with warmed 37°C calcium-free buffer followed by collagenase type II (Worthington 
Biochemical, Lakewood, New Jersey) for 15 minutes. Tissue was dissolved into a single 
cell suspension and filtered through a 70uM mesh. Cells were seeded onto polystyrene 
plates at 37C and non-adherent cells washed off after 1 hour. Cells were either collected 
immediately in Trizol reagent (Invitrogen, Carlsbad, California) for ex vivo experiments 
or passaged twice before in vitro use in complete DMEM with 20% FBS (Hyclone 
Laboratories, Logan, Utah), 1x penicillin/streptomycin, 25mM HEPES, 1x Anti-Anti, and 
1x non-essential amino acids. In killing experiments, fibroblasts were treated with 1uM 
of angiotensin II in complete DMEM for 1 hour. Cells were then washed prior to the next 
step of experiment.  
Isolation of primary NK cells 
NK cells were negatively isolated from naïve or polyI:C-treated (1mg for 24 hours) WT 
or Rag1-/- BALB/c spleens by manual magnetic cell sorting using the Mouse NK 
Isolation Kit II (Miltenyi Biotech, Bergisch Gladbach, Germany) and cultured for 24 
hours with IL12 (10ng/mL) and IL15 (5ng/mL). 
mRNA  
For qPCR, cells or tissues were homogenized in TRIzol reagent (Invitrogen, Carlsbad, 
California) and chloroform extracted. Samples were DNAse treated and cDNA libraries 
made using iScript Reverse Transcriptase Supermix (BioRad, Hercules, California). 
mRNA was amplified using Sybrgreen (Applied Biosystems, Foster City, California) and 
all values were calculated against HPRT mRNA. Values were controlled against isotype 
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control groups and shown as a function of fold induction using the formula 2-Δ(ΔCT). 
ELISA 
Samples were run using tissue homogenates in 1x PBS or cell culture supernatant using 
enzyme-linked immunosorbent assays (ELISA) kits for CCL11 (RND Biosystems, 
Minneapolis, Minnesota) or a multiplex LINCO kit (Millipore, Jaffery, New Hampshire). 
Statistics 
Multiple group comparisons were performed by ordinary one-way ANOVA, followed by 
the Tukey-Kramer post-test (if parametric), or Kruskal-Wallis, followed by Dunn’s post-
test (if non-parametric) (Graphpad Prism, San Diego, California). All statistics of 2 
groups were performed by student’s t-test. P-values less than 0.050 were considered 
statistically significant.  
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CHAPTER III: NK CELLS ARE PROTECTIVE IN EAM 
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INTRODUCTION TO NK CELLS IN MYOCARDITIS 
Biology of Natural Killer Cells 
Natural killer (NK) cells comprise part of the Type 1 compartment of the innate 
lymphoid cell (ILC) family4,97. Other ILCs include Th2-associated Type 2 ILCs and the 
Rorγt+ ILCs. ILCs are morphologically lymphocytic in nature, but lack the somatic 
rearrangement of antigen receptors found in the more classical T-cells and B-cells of the 
adaptive immune system. ILCs are responsive to multiple immune signals, are required 
for defense against pathogens, and are necessary for the formation of lymphoid organs, 
for repair to damaged tissue, and in tissue homeostasis96.  
NK cells contain pre-formed cytotoxic granules that are released upon specific 
activation signals that do not require previous sensitization and were originally classified 
as innate cytotoxic effector lymphocytes due to their stochastically expressed activation 
and inhibitory receptors and lack of memory formation98,99. Since then, they have been 
recognized for their ability to modulate the immune system well-beyond the innate 
response, but they are still the first line of defense against many intracellular pathogens99. 
The absence of NK cells results in increased viral titer and dissemination in multiple 
animal models16,23.  
NK cells classically recognize virally infected or tumor cells by their abnormal 
presentation of MHCI. MHCI on healthy cells results in the ligation of an inhibition 
receptor on the surface of NK cells, preventing the release of perforin and granzyme. 
However, NK cells have hundreds of invariant receptors that are stochastically expressed 
on each cell’s surface during development that recognize a wide variety of self and 
foreign antigens25,27. Certain viral proteins, such as influenza hemagglutin (HA) and 
28 
 
Sendai HA-neuraminadase (HN), directly ligate NK activation receptors NKp46 and 
NKp44, respectively23.  
Mouse and human NK cells are believed to have arisen through convergent 
evolution12. While many of the receptors expressed on murine and human NK cells 
recognize the same antigens and ligands, they have minimal sequence homologies100,101. 
Therefore, functional comparisons between mouse and human NK receptors are difficult, 




Development of Murine NK cells  
NK cells and CD8+ T cells share similar development characteristics26. Both arise 
from the bone-marrow sourced common lymphoid progenitor (CLP) and require 
signaling through the common-γ chain for survival and homeostasis26. Unlike CD8+ T 
cells, however, NK cells do not require trafficking to the thymus for survival and 
activation. And while most NK cells arise and mature in the bone marrow, certain rare 
subsets of NK cells have been shown to finish maturing in the liver32,34.  
Unlike the established development of T-cells in the acquisition and loss of CD4 
and CD8 markers during positive and negative selection in the thymus, NK development 
is characterized by the acquisition of arbitrary surface markers and functional ability as 
there has been no consensus reached yet on what the distinct maturation stages are 
(Figure 3). The earliest NK progenitors are non-stromal bone marrow cells known as pre-
NK progenitors (pre-NKP) that express surface makers CD117 and CD244, and the 
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transcription factor Id226,34,96,102.  
From this stage, the cells acquire CD122, the β-receptor subunit of both IL2 and 
IL15, and CD132, the common-γ chain. IL15 is required for the development and 
maturation of fully functional NK cells35,38. At this time, it is unknown what signals 
control the shift from pre-NKPs to these NKPs, though transcription factors EOMES and 
T-bet are required103. NKPs are defined as cells that express CD122 and CD132, but lack 
the functional capacities of mature NK cells and do not express other lineage markers 
such as CD3, CD19, and CD14.  These cells are considered NK-committed and do not 
develop into other cell types upon in vitro stimulation52,104.  
NKP cells undergo the maturation process into immature NK cells (iNK) upon 
stimulation with IL15, a process that can be amplified with the addition of other CD122 
and CD132 ligands IL3, IL7, c-kit ligand (KL), and flt-3 ligand (FL). The latter cytokines 
are not required for NK maturation, but are actively expressed by bone marrow stromal 
cells62,103. iNK cells express high levels of CXCR4, a receptor for the highly expressed 
stromal-factor 1 in the bone marrow, and thus are retained until maturation65. They also 
begin to express other NK-associated markers such as NKp46, NK1.1 (in C57B/6 mice), 
CD94, and CD2726.  
The exact mechanisms of NK maturation have not yet be well-delineated, though 
licensing of these cells through the ligation of MHCI with NK inhibitory receptors such 
as the Ly49 and KIR families is required105. Without MHCI contact, immature NK cells 
remain anergic and nonfunctional, explaining why MHCI-deficient mice do not undergo 
massive inflammation yet have normal numbers of NK cells105,106.  
Mature NK cells acquire the expression of DX5 and CD11b, along with various 
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organ-specific chemokine receptors that may help egress from the bone marrow to 
specific sites in the body. These mature NK cells present with fluid organ-specific 
phenotypes through differential expression of chemokine receptors, cytokine secretions, 
and inherent cytotoxic abilities107,108. Transfer of NK cells into another organ results in 
the conversion into the local NK phenotype109.  
Mature NK cells also acquire their canonical cytotoxicity functions, with 
preformed vesicles containing granzyme-B and perforin and can express cytotoxicity 
mediators Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL). 
Depending on the activation signals received, mature NK cells may also secrete various 
cytokines and inflammatory mediators, the most well-known by type I interferons, tumor 
necrosis factor alpha (TNFα), IFNγ, and IL13. 
Involvement of Natural Killer Cells in Autoimmunity 
NK cells have been found to accumulate in specific inflammatory sites in 
autoimmune diseases – in the joints of rheumatoid arthritis (RA) patients, in the skin 
lesions of psoriasis, and in the brain lesions of multiple sclerosis110,111. Recently 
diagnosed type I diabetes patients were found to have NK cells localized around their 
pancreatic islets, though in post-mortem studies these pancreatic-infiltrating NK cells 
were not found. Similarly, RA patient joints contained higher proportions of activated 
CD56bright and IFNγ production compared to periphery NK cells in the same 
individuals111,112. When isolated and co-cultured with patient monocytes, these activated 
NK cells were able to induce differentiation of these monocytes into dendritic cells, 
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signifying an active role in the immune environment113. Furthermore, individuals with 
NK-lymphoproliferative disease of granular lymphocytes, a genetic condition resulting in 
the chronic accumulation of circulating NK cells, have increased risk of developing 
autoimmune manifestations114,115.  
This data contradicts with the observation that patients with RA, Sjogren’s 
syndrome, and SLE have decreased circulating NK cell numbers and cytotoxicity 
potential112,116,117. NK cells isolated from the periphery of RA patients failed to induce 
apoptosis in MHCI- deficient K562 cells compared to NK cells from the periphery of 
healthy controls in vitro. Additionally, MS patients in remission had higher proportions of 
activated NK cells in their periphery, as defined by increased Fas expression and Th2 
cytokine secretions, than patients with active disease118. Altogether, it is not clear whether 
autoimmune diseases are exacerbated by the deficiency or excesses of NK cells, making 
animal studies necessary.   
However, studies in animal models have also resulted in a plethora of conflicting 
data. Depending on the strain of mouse and method of NK manipulation, wildly different 
disease outcomes can be observed. This is perhaps most evident in the best known of 
autoimmune disease models – experimental autoimmune encephalomyelitis (EAE).  
EAE is a model of multiple sclerosis and can be induced by immunization with 
myelin oligodendrocyte-glycoprotein (MOG), myelin basic protein (MBP), etc119. 
Depletion of NK cells from C57B/6 mice in whole protein MOG-induced EAE by NK1.1 
antibodies resulted in aggravation of disease and increased Th1 infiltration into the CNS. 
Furthermore, transfer of NK cells into mice undergoing EAE reduced disease severity120. 
However, other studies in IL18 deficient mice noted that IFNγ-producing NK cells were 
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required for the progression of disease and that depletion of NK cells from MOG-peptide 
induced EAE using NK1.1 or anti-asialo GM1 depressed disease117,121.  
Similar contradictions have been found in autoimmune animal models of insulin-
independent diabetes-mellitus, colitis, and collagen-induced arthritis110,111,113. Diabetes 
can be prevented in non-obese diabetic (NOD) mice by subcutaneous administration of 
CFA, which induced NK trafficking and secretion of IFNγ. Depletion of NK cells 
rendered CFA administration inconsequential in protection against disease 
development122. However, in two other models of diabetes, BDC2.5/NOD and 
BDC2.5/B6g7, associations were found between NK cell numbers in the pancreas and 
levels of insulitis, and depletion of NK cells limited disease severity123,124.  
In studies of NK cells both clinically and in animal models, some contradictory 
results could be attributed to difficulties in separating the NK and natural killer T-cell 
(NKT) populations. NKT cells share many of the same functions and mechanisms of NK 
cells, with the addition of a somatically rearranged T-cell recptor (TCR)125,126. NK1.1 
antibody, a widely used method for NK depletion in C57Bl/6 mice, also depletes NKT 
populations126. Anti-asialo GM-1, on the other hand, used in BALB/c mice models, 
leaves the NKT component untouched127,128.  
NK cells are distinct controllers of disease and dysregulation in their biology can 
dramatically shift clinical outcomes. Furthermore, the mechanisms by which NK cells 
alter disease are not limited to cytotoxicity. Cytokine release resulting in alteration of Th 
subtypes, direct contact-mediated lysis of auto-aggressive T cells, and accelerated 
maturation of monocytes and dendritic cells are all ways by which NK cells modulate the 
innate and adaptive immune system. Therefore, NK cells may in either protective or 
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pathogenic in progression of autoimmune disease. The lack of a consensus phenotype 
across autoimmune features may indicate that the role of NK cells may largely hinge on 
the target organ involved, as NK cells are phenotypically very diverse and are greatly 
influenced by their local microenvironment.  
Role of Natural Killer Cells in Myocarditis 
Similar to other autoimmune clinical studies, both idiopathic and viral myocarditis 
patients have severely decreased levels of natural killer (NK) cells and non-MHC 
restricted toxicity, pointing towards defects in both frequency and function129,130. The 
same was also found in DCM patients, though whether these DCM patients were 
secondary as a result of primary myocarditis is not stated131. Perforin-caused pores on the 
surface of virally-infected myocytes have been found in both clinical myocarditis patients 
and in animal viral myocarditis models132. In contradiction, heart biopsies of 18 early 
myocarditis patients did not reveal any NK cell infiltration, though it is unclear whether 
this is due to the sampling limitations133 
NK cells play an essential role in the defense against acute viral pathogens 
associated with clinical myocarditis. We and another groups have reported NK cells as 
protective against both CV3 and MCMV-induced myocarditis, though it must be said that 
these studies depleted both NK and NKT populations simultaenously85,134. The direct 
mediators of viral recognition are unknown in CBV and MCMV, though ligation of 
activating receptor Ly49H by the viral glycoprotein m157 and destabilization of 
inhibitory receptor Ly49C by abnormal MHCI expression is necessary in limiting 
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MCMV infection135,136.  
NK1.1 antibody treatment in normally chronic myocarditis-resistant strains 
C57BL/6 and BALB.B6-Cmv1r mice, which express NK1.1 on their NK cells, resulted in 
disease progression mimicking the natural progression of susceptible BALB/c MCMV- 
and CBV-induced viral myocarditis85. This indicates that NK cells play a large role in the 
determination of strain-dependent resistance to experimental myocarditis. It is unknown 
if NK cells act solely by limiting viral replication in myocarditis, reducing the 
autoimmune response, or both.137,138  
If NK cells control both viral load and inflammation in myocarditis, they would 
be an excellent candidate for targeted biologic therapy. Patients would no longer have to 
be stratified by the presence of virus in the heart and autoantibodies in the serum in order 
to determine their course of treatment as NK cells would be able to target both 
mechanisms, viral and autoimmune, simultaneously. In essence, NK cells or NK-derived 
products concurrently could serve as an anti-viral and an immunosuppressant.  
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RATIONALE 
We undertook the research in this dissertation in order to determine if natural 
killer (NK) cells or their products could modulate the pathogenesis of myocarditis in the 
absence of virus. While the protective role of NK cells in the advent of CBV or MCMV-
induced myocarditis was largely attributed to reduction of viral titer and prevention of 
inflammatory cascades, it is possible the NK cells may have limited the inflammation in a 
virus-independent manner85,93,139. EAM is a largely Th-driven disease and NK cells have 
been shown to affect polarization of Th subsets through secretion of IFNγ and by killing 
of activated antigen-specific T cells. Both of those actions would be protective in EAM, 
as IFNγ-/- mice had significantly worse disease and that CD4 myosin-specific T cells are 
the driver of inflammation94,140,141. Therefore, we hypothesized the NK cells would be 
protective in EAM. Furthermore, given the ability of NK cells to control non-pathogenic 
models of liver fibrosis through the killing of activated fibroblasts, we expected that NK 




NK cells accumulate in the heart during EAM  
To examine the kinetics of NK cell accumulation during cardiac inflammation, we 
induced EAM in male wild type (WT) BALB/c mice. Levels of NK cells in perfused 
hearts at day 21 of EAM by flow cytometry on days 0, 14, and 21 were assessed (Figure 
4A). The numbers of CD5-DX5+NKp46+ NK cells significantly increased from day 0 to 
days 14 and 21 during EAM in absolute counts, however the proportion of NK cells out 
of CD45+ cells in the heart was stable (Figure 4B and 4C). Thus, NK cell comprised a 
distinct population in the heart that actively accumulated during EAM.  
 
Cardiac NK cells secrete IFNγ and cytotoxic mediators 
To determine NK cell phenotypes in the heart, we profiled cytokine and 
cytotoxicity mediators NK cells by flow cytometry at the peak of inflammation on day 21 
of EAM and compared them against periphery NK cells from the spleen. There were 6-
fold more cardiac NK cells secreting IFNγ compared to splenic NK cells (Figure 5A). 
The two populations had equivalent IL13 expression (Figure 5B) and neither expressed 
IL5 (data not shown). Compared to spleen NK cells, significantly greater proportions of 
cardiac NK cells expressed perforin and were positive for LAMP-1, a correlate for 
granzyme B secretion (Figure 5C and 5D)142. Cardiac NK cells had increased IFNγ and 
cytotoxicity potential when compared against peripheral NK cells at the same time.  
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Cardiac NK cells upregulate certain activation markers 
We also assessed the expression of various activation and inhibitory surface 
markers on cardiac NK cells compared to peripheral splenic NK cells to determine if they 
had a distinct phenotype. Cardiac NK cells had upregulated levels of the activation 
markers CD27, TRAIL, and CD69 (Figure 6A, 6B, and 6C) with decreased levels of 
NKG2D (Figure 6D). Cardiac NK cells also upregulated levels of Ly49A/D and Ly49H 
(Figure 6E and 6F). Cardiac NK cells can be differentiated from peripheral NK cells by 
their surface marker profiles.   
ASGM-1 treatment in naïve animals selectively depletes NK cells 
To determine if NK cells could be depleted using anti-asialogangloside GM-1 
(ASGM-1) polyclonal antibody treatment and how this treated affected other cellular 
populations in naïve BALB/c animals in vivo, mice were injected for 3 days with 1mg of 
ASGM-1 i.p. Mice were sacrificed at day 4 and lungs, hearts, livers, spleens, and blood 
were collected. Cell populations were measured by flow cytometry. ASGM-1 antibody 
treatment depleted CD3-DX5+NKp46+ NK, but did not affect CD3+DX5+NKp46+ NKT 
cells or Ly6GloSiglecF+ eosinophils (Figure 7A – 7C) in naïve animals.  
ASGM-1 depletes NK, but not NKT cells during EAM 
To determine whether NK cells could be depleted using ASGM1 throughout 
EAM, NK cells were depleted in vivo using 1mg of polyclonal antibody injected i.p. from 
day -6 to day 21 of EAM as described in the methods (Figure 8A). The ASGM-1 
antibody treatment led to significant reductions in the number and proportion of CD3-
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DX5+NKp46+ NK cells (Figure 8B) in the spleen and heart during EAM. This treatment 
schedule did not alter the frequency of the CD3+DX5+ NKT cell population. Therefore, 
ASGM-1 treatment, unlike NK1.1 antibody treatment in C57BL/6 mice, is specific for 
NK cells.   
NK cells limit cardiac inflammation during EAM 
We explored whether NK cells played a role in the progression of EAM by 
depleting NK cells throughout disease and sacrificing the animals at day 21 in order to 
examine levels of cardiac inflammation. ASGM-1 treatment resulted in significantly 
more severe myocarditis on day 21 as assessed by histology (Figure 9A). This was 
mirrored by increased CD45+ infiltration in the heart as measured by flow cytometry 
(Figure 9B). The more severe disease in NK-depleted animals was also accompanied by 
increased levels of circulating anti-MyHCα614-629-specific IgG antibodies (Figure 9C). 
ASGM-1 treated animals have increased fibrosis at day 21 of EAM 
We observed accelerated cardiac fibrosis on day 21 in NK-depleted animals using 
Masson’s Trichrome staining (Figure 10A). In order to assess fibrosis quantitatively, we 
processed all images of stained heart slides through ImageJ to enumerate the percentage 
of collagen-positive (blue) pixels versus non-fibrotic (red) pixels as described in the 
methods section. NK-depleted animals had increased levels of collagen deposition 
(Figure 10A), indicating that NK cells may protect against fibrosis.  
We also quantified the active production of collagen in NK-depleted mice at day 
21 of EAM, as this was early in the disease process and most likely, cessation of collagen 
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production often seen in late stages of DCMI had not occurred. Indeed, we found that NK 
depletion lead to increased production of collagen as seen by mRNA levels of collagen 1 
and collagen 3 in the heart (Figure 11A – 11C).  
ASGM-1 treatment during EAM mildly decreases cardiac function 
To determine whether this increased collagen deposition in the heart had any 
functional consequences, we performed echocardiography on isotype control and ASGM-
1 treated animals at day 21 of disease. NK-depletion worsened heart function as shown 
by significantly decreased cardiac ejection fraction (Figure 12A), which was attributed to 
changes in LV end systolic, but not diastolic, diameter (Figure 12B and 12C). This 
change was echoed in levels of fractional shortening (Figure 12D). No changes were seen 
in LV intraventricular septal thickness (Figure 12E). The deposition of collagen may have 
limited cardiac function by preventing heart contractility.   
Activated fibroblasts are not targeted for cytotoxic killing by NK cells in vitro 
We explored whether NK cells mediated protection against cardiac fibrosis by 
killing activated resident fibroblasts as reported in models of liver fibrosis123,124. We 
isolated adult mouse cardiac fibroblasts (CFs) from naïve BALB/c mice as described in 
the methods and passaged them twice to yield a pure population of CFs with positive 
staining for alpha smooth muscle actin (α-SMA), expression of fibroblast-associated 
markers fibroblast growth factor (FGF) and vimentin, and undetectable levels of myeloid 
or lymphocyte contamination as measured by CD11b and CD3 (Figure 13A – 13G).  
Splenic NK cells were magnetically isolated in either naïve or activated states, the 
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latter being induced by polyI:C (1mg) treatment administered i.p. 24 hours prior as 
described in the methods. Activated NK cells had increased expression of NKG2D and 
CD69 compared to naïve cells (Figure 14A). CFs were first activated with angiotensin II 
(AngII) at 1uM for 1 hour, illustrated by increased vimentin mRNA (Figure 14B). CFs 
were then washed and NK cells were co-cultured with CFs for 48 hours in a 1:1 ratio. 
CFs were then stained green with calcein AM (live) and red with ethidium homodimer 
(dead) and examined using immunofluorescence microscopy. While NK cells induced 
cell death in CFs, no difference was seen between untreated and activated CFs (Figure 
14C – 14E), indicating that NK-mediated killing of activated fibroblasts during EAM was 















FIGURES AND TABLES 
Figure 3. Maturation stages and associated transcription factors of murine NK cells 
NK development is broken up to distinct stages based on surface maker expression, 
functional ability, and transcription factor expression. Common lymphoid progenitors in 
the bone marrow develop into NK-progenitors (NKPs) though transcription factors 
EOMES and T-bet are required. NKPs are committed and do not develop into other cell 
types. From this stage, NKP cells become immature NK cells (iNK) upon stimulation 
with IL15 under the control of T-bet and EOMES107,143,144.  
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A) Representative gating strategy used for CD3-DX5+NKp46+ NK cells in the heart. B) 
Absolute numbers (ANOVA p=0.002) and C) percentages (n.s.) of CD3-DX5+NKp46+ 
NK cells infiltrating the heart during days 0, 14, and 21 of EAM by flow cytometry. 
Percentages based on total CD45+ cells in the heart. Significance by ordinary one-way 





Figure 5. Cardiac NK cells secrete IFNγ and cytotoxic mediators 
 
To determine NK physiology, cardiac and splenic CD3-DX5+NKp46+ NK cells were 
stained at day 21 of EAM. Percentage of A) IFNγ (p<0.001), B) IL13 (n.s.), and C) 
perforin (p<0.001) positive cells were based on positive intracellular antibody staining 
after 4-6 hours of PMA/ionomycin stimulation and Golgistop in vitro. D) Percentage of 





Figure 6. Cardiac NK cells upregulate certain activation markers 
To determine the cell surface phenotype of cardiac and splenic NK cells at day 21 of 
EAM, NK cells were examined by flow cytometry. Percentage of NK cells positive for 
activation-associated markers A) CD27, B) TRAIL, C) CD69, and D) NKG2D. 
Percentage of NK cells positive for inhibitory receptors E) Ly49AD and F) Ly49G. 
Significance for A-F calculated by unpaired t-test.  
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Figure 7. ASGM-1 treatment in naïve animals selectively depletes NK cells 
Percentage of A) CD3-DX5+NKp46+ NK cells, B) CD3+DX5+NKp46+ NKT cells (all 
n.s.), and C) Ly6GloSiglecF+ eosinophils (all n.s.) in the liver, heart, lung, and spleen of
naïve WT mice after three days of rabbit IgG or ASGM-1 treatment of 1mg of antibody 
per day. All statistics calculated by unpaired t-tests.  
46 
 
Figure 8. ASGM-1 depletes NK, but not NKT cells during EAM 
Day -6   0   21
1 mg every day                                                 1 mg every other day
 
A) Schematic of rabbit IgG and ASGM-1 antibody treatment schedule throughout EAM. 
Percentage of B) CD3-DX5+NKp46+ NK cells in the heart (p<0.001) and spleen 
(p<0.002) and C) CD3+DX5+ NKT cells out of CD45+ cells (all n.s.) of rabbit IgG and 















A) Histology scores and representative histology of H&E stained cardiac sections from 
PBS, rabbit IgG, and ASGM-1 antibody treated animals at day 21 of EAM (ANOVA 
p<0.001). B) Total CD45+ cells infiltrating the hearts of isotype control and ASGM-1 
treated animals at day 21 of EAM as assessed by flow cytometry (p<0001). C) Levels of 
anti-MyHC614-629 total IgG antibodies in the serum of PBS, isotype control, and ASGM-1 




Figure 10. ASGM-1 treated animals 
have increased fibrosis at day 21 of 
EAM 
A) Representative histology of
Masson's Trichrome stained cardiac 
sections from rabbit IgG, and 
ASGM-1 antibody treated animals at 
day 21 of EAM. B) Enumeration of 
fibrosis from Masson’s Trichrome 
slides by calculation of red versus 
blue pixels on ImageJ software 
(p=0.042). Statistics calculated by 
unpaired t-test.  
Isotype   ASGM-1
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Figure 11. NK cells limit collagen deposition during EAM 
Collagen production as measured using qPCR for A) collagen 1a1 (p=0.04), B) collagen 
1a2 (p=0.03), and C) collagen 3a1 (p=0.02) for mRNA in hearts of rabbit IgG and 
ASGM-1 treated animals at day 21 of EAM. Values calculated as a function of HPRT 
levels and compared against rabbit IgG. Statistics calculated by unpaired t-test. 
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Cardiac phenotypes of PBS, isotype 
control, and ASGM-1 treated animals at 
day 21 of EAM. A) Ejection fraction 
(p=0.026) as calculated as from fractional 
shortening and left ventricular diastole and 
systole. B) Left ventricular end diastolic 
dimension (LVEDd) (n.s.) and C) left 
ventricular end systolic dimension 
(LVEDs) (p=0.03). D) Fractional 
shortening (p=0.04) and E) intraventricular 
septum diameter (IVS) (n.s.) as measured 
by echocardiography. Statistics by ordinary 
one-way ANOVA with post-testing by 
Tukey’s multiple comparisons test.  
Figure 12. ASGM-1 treatment during EAM mildly decreases cardiac function 
51 
Figure 13. Cardiac fibroblasts can be isolated from adult mice 
α-smooth muscle actin Rabbit IgG 
10x 10x
40x 40x
A) Bright-field and B) immunofluorescence images of adult mouse cardiac fibroblasts
(CFs) isolated and passaged twice, fixed with 4% paraformaldehyde and stained with 
1:1000 anti-alpha smooth muscle primary rabbit antibody or rabbit IgG isotype antibody 
and 1:200 anti-rabbit rat FITC-conjugated antibody. Levels of C) fibroblast growth factor 
and D) vimentin mRNA as measured by qPCR relative to HPRT in untreated CFs and 
naïve BALB/c whole heart homogenates. Levels of D) vimentin, E) CD11b, and F) CD3 
mRNA as measured by qPCR relative to HPRT in untreated CFs and bone marrow and 
M-CSF derived monocytes. 
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Figure 14. Activated fibroblasts are not targeted for cytotoxic killing by NK cells in vitro 























A) Expression of NKG2D and CD69 in splenic NK cells isolated from naïve or polyI:C
treated mice after 24 hours. B) Levels of vimentin mRNA measured by qPCR in isolated 
CFs after no treatment or angiotensin II (AngII) treatment (1uM) for 1 hour as controlled 
by HPRT (p=0.02). C) Representative images of live and dead no treatment and AngII 
treated CFs after 48 hours of 1:1 co-culture with naïve or polyI:C activated NK cells. 
Percentage of live CFs after 48 hours of co-culture with D) naïve and D) activated NK 
cells as determined by red versus green positive cells counted manually on ImageJ 
software. Statistics for B calculated by unpaired t-test and C and D by one way ANOVA 
with Tukey’s post-testing.  
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DISCUSSION 
Given the role of NK cells in the mediation of viral myocarditis and their newly 
understood ability to mediate the adaptive immune system, we hypothesized that NK 
cells may play a role in the pathogenesis of EAM. Indeed, we provide the first 
examination of inflammatory cardiac NK cells and show that they represent a distinct and 
activated population compared to NK cells found in the spleen. Their accumulation in the 
heart suggests that they are recruited during EAM, though the mechanism of recruitment 
is unknown. It is postulated that their recruitment and trafficking is dependent on the 
target cell whether tumor, virally-infected, or MHCI-mismatched cells and the organ in 
which these cells reside145-147. We did not explore the mechanism of NK trafficking in 
cardiac inflammation in this dissertation, and CFA may induce trafficking of NK cells to 
lymphoid nodes through the triggering of L-selection on NK cells148. Any studies would 
be better served in T-cell adoptive transfer-induced EAM to separate out the confounding 
effects of CFA94.  
Cardiac NK cells upregulated levels of surface markers Ly49A/D and Ly49H, 
consistent with a mature and activated phenotype. Immature NK cells found in the bone 
marrow are largely Ly49 negative144,149. A larger proportion of NK cells in the heart 
expressed CD27, expressed on a mature and cytotoxic NK subset thought to produce high 
levels of IFNγ, though in our model no difference was found between IFNγ production in 
CD27+ and CD27- subsets in the heart (data not shown)150,151. TRAIL, linked to the 
ability of NK cells to kill activated and virus-infected T cells, was also increased in the 
heart. Upregulation of TRAIL-death receptor (TRAIL-R2) on hepatitis virus B (HBV)-
specific CD8+ T cells was required for NK mediated killing152. CD69, along with 
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increased IFNγ production, is one of few phenotypic markers that can distinguish 
activated pancreatic NK cells from diabetic NOD mice compared to pancreatic NK cells 
from diabetes-free strains153.  
NKG2D, surprisingly, was the only significantly downregulated marker queried 
on cardiac NK cells. NKG2D is a potent activation receptor also expressed on NKT, and 
δγ T-cells and recognizes a subset of stress-induced MHCI-like molecules104. 
Dysregulation of NKG2D has been implicated in the breakdown of self-tolerance in 
multiple autoimmunity models154,155. Prevention of diabetes in NOD mice is possible by 
administrating anti-NKG2D antibodies, preventing NK cells from recognizing the ligand 
Rae1 on pancreatic islet cells106. Expression of NKG2D on CD4+ cells is correlated with 
disease severity in Crohn’s patients and is enriched in the synovial fluid in RA. In all 
these studies, total NKG2D was targeted109,120. Therefore, the functional role of NKG2D 
on NK cells specifically has not been determined in autoimmune models, and in our 
model of EAM, the downregulation of their expression indicates it may play a minimal 
role.  
Besides their cytotoxicity potential, NK cells modulate the immune environment 
by the secretion of cytokines. NK cells may be functionally polarized by the same 
cytokine profiles that alter T-cell phenotypes156,157. IFNγ is the prototypical cytokine 
produced by activated NK cells. IFNγ is induced largely by IL2, though secretion can 
also be triggered by IL1, IL12, IL18, and TNFα158. However, NK cells can be induced to 
express Th2 type cytokines IL5 and IL13 through IL4 and also by IL12 in IFNγ-deficient 
mice159,160. NK cells in the heart during the peak of EAM produced IFNγ as their 
principal cytokine.  
55 
In this dissertation, we depleted NK cells by the administration of ASGM-1 
antibody which left the NKT population intact in both naïve and inflamed animals. Thus, 
unlike many studies targeting NK1.1 expressed on both NK and NKT cells, we do not 
attribute alterations in phenotype to changes in the NKT compartment, though they also 
have been shown to have immune-modulatory roles in autoimmunity and inflammation. 
ASGM-1 treatment did, however, affect basophil populations (see Chapter 3). 
Surprisingly, the multiple injections of polyclonal rabbit IgG, as evidenced by the rabbit 
isotype controls, did not have any effects on disease severity, whether in positive manner 
by mimicking IVIG treatment as seen in rat isotype control antibodies or in a negative 
manner through the development of anti-rabbit IgG antibody complexes.  
The depletion of NK cells led to increased inflammation and collagen deposition 
in the heart during in the inflammatory stages of EAM. As we did not examine the 
animals past day 21 of disease, the effects of NK cells on DCMI are unknown. ASGM-1 
treated animals had decreased LV ejection fractions compared to control animals 
ultimately due to alterations in LV end systolic dimensions (LVEDs) with no changes in 
the LV end diastolic dimensions (LVEDd) seen of a dilated phenotype118,122. Furthermore, 
while there were significantly drops in the cardiac output, none of the animals had the 
drastic reduction see in mouse models of heart failure161-163. We attribute the changes in 
systolic dimensions to the increased inflammation and collagen levels limiting the ability 
of the heart to contract. It is certainly possible that NK cells play a role in the 
development of DCMI given the increased collagen seen this early timepoint, but 
assessment of the mice at day 42 or later after the peak of inflammation subsides would 
be necessary.  
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While the cardiac NK cells profiled had increased expression of perforin and 
granzyme-B, their absence in the heart led to increased collagen deposition in the heart 
during myocarditis. Studies have indicated that NK cells can protect against the 
development of liver fibrosis by the specific targeting of activated hepatic stellate cells 
(HSCs) in 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), carbon tetrachloride and 
HCV models121,123,124. Therefore, we hypothesized that NK cells limited fibroblasts 
through the killing of activated fibroblasts before collagen could be deposited. However, 
in series of co-culture experiments, we did not find that the co-culture of NK cells with 
activated fibroblasts resulted in any increase in death when compared to untreated 
fibroblasts. 
While it would be ideal to have used activated NK cells directly from the heart of 
animals undergoing EAM, this is not feasible given the relatively small number of NK 
cells found in the heart during disease compared to the numbers required for an in vitro 
culture. We instead used polyI:C activated NK cells, known to increase their cytotoxicity 
potential, as an alternative99. Both naïve and activated cells, though the latter population 
had upregulated expression of activation markers NKG2D and CD69, they also did not 
selectively target activated fibroblasts. Also, given the organ-specific properties of NK 
cells, it is likely that the mechanism of protection against fibrosis in the liver, associated 
with NKG2D expression, may widely differ from inflammatory cardiac NK cells107,108.  
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CHAPTER IV: EOSINOPHILS ARE REQUIRED FOR NK-
MEDIATED PROTECTION OF EAM 
58 
INTRODUCTION TO THE INTERPLAY OF EOSINOPHILS AND NK CELLS 
IN EAM 
Biology and Development of Eosinophils 
Eosinophils are innate granulocytes that comprise 1-3% of circulating peripheral 
blood cells164. They are short-lived, with a lifespan of approximately 8 – 18 hours in the 
periphery. Upon migration into the tissue through diapedesis, eosinophils have a lifespan 
of 2-5 days depending on the inflammatory state of their microenvironment and up to 14 
days in vitro165. Most eosinophils will traffic to the digestive system, where they will line 
the lamina propria of the gastrointestinal tract under the control of eotaxin-1 (CCL11), 
though not eotaxin-2 (CCL24)166. Under steady stage conditions, eosinophils will also 
largely home to the mammary gland, thymus, and uterus, the latter being influenced of 
estrogen167.   
Eosinophils develop in the bone marrow from common myeloid progenitor 
(CMP) cells derived from multi-potent hematopoietic stem cells (HSC). These CMP cells 
give rise to a myeloblast believed to be the common progenitor for both basophils and 
eosinophils. From there, development into an immature eosinophil is regulated by 
transcription factors PU.1, GATA-1, and C/EBP168. Mice lacking the GATA-1 promoter 
fail to develop mature eosinophils, though other cell lineages are unaffected169.  
Maturation and trafficking from the bone marrow in the periphery is under the 
control of IL5, with additive effects from GM-CSF and IL3170,171. Intravenous injection 
of IL5 leads to high levels of peripheral eosinophils, a phenotype that is mirrored in 
multiple IL-5 transgenic models172,173. IL5-deficient mice have severely reduced numbers 
of eosinophils and limited response to allergic or asthmatic stimuli174. 
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Eosinophils are known for the tissue injury they can cause upon the release of 
their pre-formed granules of cationic and enzymatic proteins. Of these, major basic 
protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and 
eosinophil-derived neurotoxin (EDN) are the best characterized. Administration of 
purified MBP, EPO, and ECP to heart, brain, tumor, and epithelial tissue leads to cell 
damage and tissue death175-177. ECP has both cytotoxic effects by causing the formation 
of pores in target cells and non-cytotoxic effects in the suppression of T and B cells 
responses, degranulation of mast cells, and stimulation of mucus production in airway 
epithelium178. MBP induces mast cell and basophil degranulation while affecting smooth 
muscle contraction and nerve plasticity179,180.  
Eosinophils can also secrete a number of cytokines such as IL2, IL4, IL13, and 
IL5, that can ultimately affect T-cell activation, differentiation, and proliferation181.  
They also can regulate Th1 differentiation through the release of indoleamine 2,3-
dioxygenase (IDO), whose end-product, kyneurines (KYN), promotes the apoptosis of 
Th1 cells182. There have also been reports that eosinophils can serve as antigen-presenting 
cells (APCs) under certain disease conditions such as asthma183-185. Eosinophils have also 
been shown to be required for repair of muscle injury and in the development of certain 
adipose cells through the recruitment of progenitor populations186,187. Altogether, the 
mechanisms by which eosinophils modulate the immune system and local tissue 
environments, whether pathogenic or protective, can vary widely with each disease and 
should be determined on a case-by-case disease basis.  
Eosinophils traffic to and infiltrate sites of injury and inflammation in response to 
a wide variety of signals. While IL5 appears to be the main controller of egress from the 
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bone marrow, the best known local positive chemotactic mediators include CCL11, 
CCL24, and CCL26 (human only), IL33, and prostaglandins168,170. Conversely, they are 
negatively regulated through chemokines CXCL9 and CXCL10, which are recognized 
through receptors CXCR9 and CCR3 188-190. Eosinophils pre-treated with CXCL9 and 
CXCL10 fail to response to CCL11 and do not traffic to the lung when transferred into 
animals undergoing ovalbumin (OVA)-mediated models of asthma.  
Eosinophils in asthma models have perhaps been best studied due to the close 
association between Th2 pathways and eosinophilic processes, though no single mediator 
of trafficking and accumulation has been determined. CCL11 and CCL24, traditionally 
upregulated by Th2-related cytokines IL4 and IL13, are major mechanisms of 
eosinophilic trafficking – eotaxin receptor (CCR3)-deficient mice display severely 
depressed levels of eosinophils in the lung and bronchial tubes in response to respiratory 
challenge of OVA following subcutaneous OVA-sensitization191. Only a limited reduction 
was seen, however, when CCR3-deficient mice were sensitized systemically192. Other 
studies have shown vital roles for various adhesion factors expressed on the surface of 
eosinophils in their entry into inflammatory sites – very late activation antigen 4 (VLA-4) 
and vascular cell adhesion molecule 1 (VCAM-1) expression on eosinophils is required 
for their infiltration during antigen-induced bronchial hypersensitivity193-195.  
Interactions between eosinophils and their closely-related counterparts, mast cells 
and basophils, have also been major mechanisms of eosinophil regulation during disease. 
Certainly, all three are major components of most allergic inflammatory processes and 
express many of the same receptors and cytokines, such as IgG (FcγRII/CD32) and IgA 
(FcαRI/CD89) receptors and IL4, IL5, and IL13196. All also express the IgE 
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receptor FcεR1, although eosinophils express this to lesser extent. Furthermore, 
eosinophil MBP can trigger degranulation of mast cells and basophils that may, in turn, 
result in the release of eosinophilic activation signals. 
It has recently been shown that ILC2 cells residing in peripheral tissues are 
required for the maintenance of eosinophils131,132. These cells are responsible for the 
maintenance of serum IL5 responsible for the egress of eosinophils out of the bone 
marrow. IL33 is a potent stimulator of ILC2s, and treatment of naïve mice with IL33 
induces pericarditis163. Stimulation of ILC2s in lung helmith infections results in the 
upregulation of both IL5 and IL13, inducing the expression of eotaxins and adhesion 
molecules on endothelial cells. This ultimately results in the onset of eosinophilia in the 
lung tissue132.    
Hypereosinophilic syndrome and secondary presentations 
Eosinophilia is defined as the abnormal enrichment of eosinophils in the periphery 
blood197. This can be divided into two clinical subtypes: mild eosinophilia at less than 
1.5x109 cells per mL but higher than normal blood eosinophilic counts and marked 
eosinophilia at greater than 1.5x109 cells per mL. Eosinophilia is a characteristic 
secondary feature of multiple disorders and infections and often occurs in selected tissues 
where inflammation is occurring197. Tissue eosinophilia is characterized by the heavy 
presence of infiltrating eosinophils and, oftentimes, the deposition of eosinophilic granule 
proteins such as MBP 198,199.  
Allergic reactions make up 80% of patients presenting with eosinophilia in the 
western hemisphere, with helminth infections comprising the majority of the remaining 
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20%200. In both these cases, eosinophilia is attributed to the increased in Th2 cells and 
subsequent secretion of eosinophilic chemotaxis-associated cytokines IL4, IL5, and 
IL13201,202. In a small minority of cases, the underlying cause of elevated eosinophils are 
unknown, resulting in a diagnosis of idiopathic eosinophilia.  
Hypereosinophilic syndrome (HES), a subset of idiopathic eosinophilic 
pathologies, is characterized by an eosinophil-dominant infiltration where eosinophils 
counts are higher than 1500/mm3 in tissue and/or persistent eosinophilia of 1.5 × 109/L 
blood for more than six months203. HES may or may not be associated with specific organ 
damage and patients should first be examined to ensure that this eosinophilia is not 
secondary to parasitic infections, chronic eosinophilic leukemia (CEL), allergic reactions, 
or collagen vascular diseases (Table 5). CEL remains the most difficult to distinguish 
from HES due to significant overlap in clinical presentations, though the presence of 
FIP1L1-PDGFRA mutations associated with CEL can help differentiate diseases204,205.  
Clinical presentations of HES vary widely. A subset of patients may go on to 
develop significant tissue injury mediated by the release of eosinophilic granules 
containing EPO, ECN, MBP, and ECP.206,207 This is frequently seen in the heart, lungs, 
and skin. However, eosinophilic injury may also target the nervous system and the 
digestive tract. It is unknown what triggers the release of these granules in some patients, 
but not others208. Animal models of HES are limited, though HES may be induced by 
transgenic expression of IL5 under the CD2 or CD3 promoter209,210.  
The first line of therapeutic intervention for symptomatic HES is corticosteroids. 
In non-symptomatic patients, no therapy is required and patients are closely monitored 
for signs of tissue injury. The majority of patients respond to steroid treatment and may 
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be slowly weaned off as eosinophil levels decrease. If unresponsive to corticosteroids, the 
addition of interferon-alpha has proven beneficial206-208. The use of an anti-IL5 antibody 
known as mepolizumab as an alternative to corticosteroids has been met with limited 
success211.  
Eosinophils in Autoimmunity 
The composition of local infiltration in inflammatory disorders often determines 
the prognosis of the patient212,213. In the case of eosinophils, a strong correlation between 
cellular frequency and poor clinical outcomes are reported frequently in both 
asthma/allergy and autoimmune models214-216. Thus, clinical necrotic eosinophilic 
myocarditis is strongly associated with the most severe pathology among the multiple 
myocarditis subsets. This subset is not associated with a peripheral eosinophilic disorder, 
but can develop unexpectedly from yet-unidentifiable triggers. Patients typically develop 
severe cardiac eosinophilic infiltration, elevated cardiomyocyte death, and 
intraventricular thrombi213,217-219.  
Necrotizing eosinophilic myocarditis is characterized by extensive cardiac 
eosinophilic infiltration, pronounced cardiomyocyte death, formation of intraventricular 
thrombi, and a case fatality rate of 50%.213,218-222 Similar correlations between eosinophil 
frequency in the infiltrate and poor clinical outcomes have been reported in other chronic 
inflammatory disease models, including asthma, inflammatory bowel disease (IBD), and 
experimental autoimmune encephalomyelitis (EAE).215,216,223  
Recent studies have demonstrated that infiltrating eosinophils significantly 
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increased disease severity in CBV-induced myocarditis when mice were injected with 
IL33. Administration of soluble ST2, an IL33 receptor decoy, prevented eosinophilia and 
significantly reduced viral myocarditis without altering viral burden163. Similarly, IFNγ-/-
IL17A-/- mice display massively inflamed hearts and up to 50% fatality by day 21 of 
EAM, a phenotype that is reversed in the absence of eosinophils by crossing these 
animals to dblGATA1 mice224. Furthermore, eosinophilic infiltration in clinical 
myocarditis is strongly associated with negative clinical outcomes, supporting our 
findings.217-220
Interplay of Eosinophils and Natural Killer Cells 
NK cells are not major producers of eosinophilic mediators, with the exception of 
IL5. IL5, as a major mediator of eosinophil egress from the bone marrow into the 
peripheral blood, is a potent eosinophil chemoattractant and has been shown to be 
secreted by NK cells in asthma225,226.  
Depletion of NK cells using NK1.1 and ASGM-1 antibodies decreased 
eosinophils in the bronchoalveolar lavage fluid (BAL) prior to challenge with OVA, this 
being attributed the lack of IL5 from NK cells227. Another study showed that in mice 
were challenged with OVA, treatment of mice with NK1.1 resulted in the increased of 
eosinophils in the BAL, but further dissection of this using CD1d1-deficient mice 
indicated this was due to effects from the NKT compartment226,228.   
Recently, studies have shown that NK cells may directly induce apoptosis in 
eosinophils. Awad et al showed that NK cells isolated from human healthy PBMCs 
induced the activation and apoptosis of eosinophils as measured by CD62L and CD69 
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when co-cultured together in vitro. Apoptosis was initiated due to increases in reactive 
oxygen species (ROS) in eosinophils and cell death could be mitigated through the use of 
mitochondrial inhibitors rotenone and antimycin229.  
Barnig et al demonstrated that NK cells from asthmatic patients were increased 
and more highly activated in the blood than those from healthy donors. NK cells isolated 
from asthmatic patients expressed increased levels of CD69, NKG2D, and ALX/FPR2, a 
receptor for lipoxin A4 (LXA4). LXA4 is elevated in the lungs of asthmatics and 
administration limits bronchoconstriction. Furthermore, LXA4 decreased eosinophilic 
trafficking and also limits NK cytotoxicity. The addition of LXA4 to co-cultures of NK 
cells and eosinophils isolated from the blood of both healthy and asthmatic donors 
limited the level of eosinophilic apoptosis230.  
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RATIONALE 
In the previous chapter, we delineated the ability of NK cells to alter the 
phenotype of EAM through the limitation of cardiac inflammation and reduction of 
cardiac output due to increased infiltration and collagen deposition in the myocardium. 
We determined that cardiac NK cells have high cytotoxicity potential through increased 
perforin and granzyme-B and expressed largely IFNγ, with limited utility of the Th2-
associated cytokines IL5 and IL13. However, we showed that despite cytotoxic potential 
and indicators from liver fibrosis models, NK cells did not directly kill cardiac fibroblasts 
in vitro.  
In this chapter, we aim to explore the mechanisms by which NK cells control 
disease pathogenesis. Given the broad range of cell types that NK cells could potentially 
alter, we expected that depletion of NK cells might have a variety of effects on the 
cardiac infiltrate. We hypothesize that the depletion of NK cells would result in the 
expansion of CD4 T cells in response to immunization, specifically in the Th2 and Th17 
components, given the IFNγ production from NK cells. Furthermore, this expansion in 
Th2 and Th17 cells would be the driver of pathogenesis through the modulation of 
monocyte populations, similar to other findings in our lab36,140,231,232.  
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RESULTS 
Eosinophils are increased in the absence of NK cells during EAM 
To determine the mechanism of NK-mediated suppression of cardiac inflammation, we 
performed comprehensive flow cytometry to examine cardiac infiltrate changes during 
EAM following NK depletion. NK-depleted animals had increased SSChiCD45+ 
granulocytic cells (Figure 15A). We analyzed which granulocyte population was 
responsible for the escalation and found that SSChiLy6GloSiglecF+ eosinophils increased 
2-fold on day 14 and 10-fold on day 21 in NK-depleted animals compared to isotype 
control animals (Figure 15B – 15C). No changes were seen in SSChiLy6Ghi neutrophils 
on day 14 and 21 (Figure 15D – 15E).  
Eosinophils in the heart of ASGM-1 treated mice have an activated profile 
We examined the phenotype of these infiltrating eosinophils to determine their 
maturation and activation status. MBP is largely post-transcriptionally regulated and is 
released into the tissue upon activation. Therefore, we stained paraffin-embedded cardiac 
tissue section with rat anti-MBP primary antibody (1:500) followed by donkey anti-rat 
IgG secondary antibody conjugated to Texas Red and counterstained samples with 4',6-
diamidino-2-phenylindole (DAPI) to distinguish cell nuclei. ASGM-1 treated animals 
showed positive staining for MBP presence (Figure 16A). SiglecF and CD11b are 
markers of eosinophilic activation. In order to determine whether eosinophils in the heart 
at day 21 of EAM in NK-depleted animals represented an activated and deliberate subset 
compared to those in the periphery, we examined SiglecF and CD11b mean fluorescence 
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intensity (MFI) on cardiac and splenic Ly6GloSiglecF+ eosinophils and found that cardiac 
eosinophils had upregulated levels of SiglecF and CD11b (Figure 16B and 16C)  
 We also profiled the mRNA transcriptome of heart-infiltrating eosinophils at day 
21 of EAM compared to spleen eosinophils. Consistent with an activated and mature 
phenotype, cardiac eosinophils downregulated mRNA levels of epx and prg2 (Figure 17A 
and 17B). They also expressed more activation associated mediators IL1β, CCL11, and 
IL6, and showed no changes in TGFβ, IL4, IL13, CCL24, or IL10 (Figures 17C – 17J)  
by qPCR, normalized to levels of HPRT. In summary, eosinophils infiltrating the heart at 
day 21 of ASGM-1 treated mice represent a distinct and activated subset population 
compared to cells in the periphery.  
 
NK depletion has no effect on mast cells or myeloid cells during EAM 
The proportions of FcεRIα+cKit+ mast cells remained unchanged in response to 
ASGM-1 treatment (Figure 18A). Along with this, levels of IL33 and ST2, known mast 
cell-derived mediators of eosinophilic accumulation, also remained unaltered (Figure 18B 
and 18C). However, basophil populations, consistent with published literature, were 
depleted in response to ASGM-1 treatment during EAM (Figure 18D). Therefore, 
although mast cells may play an undeniable role in many models of allergy, asthma, and 
autoimmunity, it is unlikely that mast cells play a major role in the modulation of disease 
pathogenesis or eosinophilic accumulation in response to NK depletion in this model of 
myocarditis.  
 Myeloid–derived populations generally make up the bulk of infiltrating cells in 
the heart during EAM and are major players in the modulation of disease. We profiled 
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total CD11b+ monocytes from isotype control and ASGM-1 treated mice with EAM and 
saw that there was no alterations in proportions of total monocytes (Figure 19A) 
Furthermore, we examined monocyte subsets based on Ly6C expression and found no 
changes in inflammatory Ly6Chi or resident-type Ly6Clomid monocyte proportions (Figure 
19B – 19C). We also looked at levels of CD11c+ dendritic cells, as these cells are major 
mediators of autoimmunity through the presentation of self-antigen to T cells, but no 
changes were found (Figure 19D). It is unlikely that the shifts in disease severity due to 
NK depletion are from alterations in the myeloid compartment.  
NK depletion increases Th2 and Th17 proportions at later stages of EAM 
EAM is a T-cell mediated disease that can potentially be influenced by antibody 
deposition so we examined proportion of infiltrating B cells and T cells at day 21 of 
EAM in ASGM-1 treated and isotype control mice. We saw no shifts in the proportions of 
total CD19+ B cells or CD3+ T cells (Figure 20A and 20B). We further examined CD4+ 
and CD8+ T cell compartments and noted that these were also unaltered by NK depletion 
(Figure 20C and 20D). 
As EAM severity can be influenced by shifts in the polarization of CD4 
populations,36,216,233 we examined how depletion of NK cells affected Th1, Th2, and Th17 
populations on days 14 and 21 of EAM in WT heart by flow cytometry. No changes in 
IFNγ+ Th1 cells were found (Figure 21A). However, IL13+ Th2 and IL17A+ Th17 cells as 
a fraction of total CD3+CD4+ cells significantly increased at day 21 of EAM (Figure 21B 
and 21C). It should be noted that due to known difficulties with IL4 antibody staining, 
IL13 was used as a surrogate marker for Th2 polarization.  
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The finding of elevated Th2 and Th17 populations at day 21 of EAM was 
supported by examining cardiac mRNA expression of Th-associated cytokines on day 21 
of EAM. qPCR data showed significant increases in Th2-associated il5 and Th17-
associated il6 in the hearts of ASGM-1 antibody treated mice (Figure 22A and 22E). 
Interestingly, we observed decreased IL17A in contrast to increased Th17 CD4+ cells 
(Figure 22C). This likely reflects the loss of NK-sourced IL17A. We found no changes in 
levels of ifng, il10, il13, and il12b (comprising both IL23 and IL12) (Figure 22B – 22G). 
Thus, NK depletion increased Th2 and Th17 associated cytokines on day 21 of EAM. 
Eosinophils are essential for increased myocarditis severity in the absence of NK 
cells 
To establish if the greater EAM severity in NK-depleted animals depended on the 
influx of eosinophils in the heart, we depleted NK cells from eosinophil-deficient 
ΔdblGATA1 mice.169 We used the same protocol as described previously for NK cell 
depletion and sacrificed the mice on day 21. Due to the lack of eosinophils in 
ΔdblGATA1 mice, NK depletion had no effect on eosinophil numbers (Figure 23A) in 
contrast to the WT phenotype (Figure 23C and 23D). This lack of eosinophils resulted in 
comparable EAM levels between NK depleted and isotype ΔdblGATA1 groups (Figure 
23B). Depletion of NK cells from ΔdblGATA1 mice had no effect on heart function and 
cardiac fibrosis compared to WT animals undergoing EAM (Figure 23C and 23D). Our 
results demonstrate from the first time that the absence of NK cells leads to more severe 
pathology through increased eosinophilic infiltration. 
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Th-dysregulation in the absence of NK cells is independent of disease severity 
To determine if the alterations in disease severity from eosinophils in ASGM-1 
treated mice were primarily due to changes in Th compartments and their associated 
cytokines, we profiled the whole heart tissue homogenates of ΔdblGATA1 for their 
expression of IFNγ, IL4, IL6, and IL17A mRNA at day 21 of EAM after isotype control 
or ASGM-1 treatment as surrogate indicators for Th populations. We show that in the 
absence of eosinophils and changes in disease severity, increases of IL4 and IL6, the 
major effector cytokines of Th2 and Th17 cells, are still seen (Figure 24A – 24D). Thus, 
shifts in Th populations still occur in NK depleted animals with limited changes to 
clinical severity in the absence of eosinophils.   
NK cells prevent production of eosinophilic chemokines in the heart during EAM 
To investigate the mechanism of eosinophil accumulation in the heart, we 
assessed the relative cardiac versus splenic expression of eosinophil-related chemokines 
in NK-depleted and isotype control animals during EAM. mRNA levels of ccl11 
(eotaxin-1) and ccl24 (eotaxin-2), chemoattractants for eosinophils, were comparable on 
day 14 (Figure 25A and 25B); however, CCL11 was significantly greater in NK-depleted 
animals by day 21 (Figure 25C).  
Chemokines CXCL9 (MIG) and CXCL10 (IP10) are known negative regulators 
of eosinophil trafficking234. On day 14, cxcl9 was significantly decreased in the NK-
depleted group with cxcl10 trending (Figure 25D and 25E). Therefore, NK cells can 
control the expression of positive and negative regulators of eosinophilic trafficking in 
the heart during EAM. 
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NK cells control eosinophil-related chemokine expression in cardiac fibroblasts 
NK cells themselves are not major producers of eosinophilic chemokines99,235,236 
and with the exception of eosinophils, there were no changes in inflammatory 
populations during EAM. We have found recently that cardiac fibroblasts (CFs) are a 
major source of chemokines and cytokines during EAM.232 Therefore, we investigated 
the ability of NK cells to control chemokine production from CFs. CFs and NK cells 
added (1:2 ratio) for 96 hours with IL4 (10ng/mL) to mimic an environment favorable for 
eosinophilic accumulation.  
NK cells suppressed IL4-mediated CCL11 production from CFs (Figure 26A). 
Additionally, NK cells significantly increased expression of CXCL9 and CXCL10, two 
negative regulators of eosinophil trafficking (Figure 26B and 26C). This pattern was seen 
for other chemokines that promote trafficking of myeloid cells, T cells, and neutrophils 
including CCL2 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), and CXCL1 (KC), 
although these chemokines are associated with the positive regulation of eosinophil 
trafficking (Figure 26D–26G). IL5, a potent eosinophilic growth factor and 
chemoattractant, was produced by CFs in the presence of IL4, although levels did not 
change upon addition of NK cells (Figure 26H).  
We further confirmed the ability of NK cells to downregulate CCL11 and CCL24 
from resident fibroblasts in vivo by isolating CFs from NK-depleted and isotype control 
hearts on day 21 of EAM. mRNA expression of ccl11 and ccl24 were increased in the 
fibroblasts isolated from NK depleted animals when compared to rabbit IgG treatment 
(Figure 27A and 27B). Thus, NK cells directly control eosinophil-related chemokine 
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expression in cardiac fibroblasts in vitro and in vivo.    
CCL11 and CCL24 are not required for NK-mediation of eosinophils 
These chemokine data presented us with two non-exclusive mechanisms by which 
NK cells regulate eosinophil trafficking: a) suppressing CCL11/CCL24-mediated 
recruitment or b) increasing CXCL9/CXCL10-mediated inhibition of trafficking. We 
investigated these mechanisms independently. To address the hypothesis that NK cells 
downregulate eosinophil accumulation by suppression of eotaxins, we employed mice 
deficient in CCR3, the sole receptor of CCL11 and CCL24234. Depletion of NK cells in 
CCR3-/- mice still resulted in the influx of eosinophils into the heart during EAM (Figure 
28A and 28B), indicating that NK cells do not mediate eosinophil accumulation in the 
heart only through the eotaxin/CCR3 pathway. 
IFNγ is not required for NK-mediation of eosinophils 
To investigate our secondary hypothesis that NK cells suppress eosinophils by 
upregulating negative chemokines CXCL9 and CXCL10, we employed IFNγ–/– mice, as 
both chemokines are dependent on IFNγ. NK cells were unable to downregulate CCL11 
and upregulate levels of CXCL9, and CXCL10 from IFNyR1-/- CFs in vitro, suggesting 
IFNγ as the major mediator (Figure 29A – 29C).  
Furthermore, we compared levels of CCL11, CXCL9, and CXCL10 in WT and 
IFNγ-/- mice at day 21 of EAM. We saw significant decreases in the protein levels of 
CXCL9, though there were no changes in levels of CCL11 or CXCL10 in the hearts of 
IFNγ-/- animals, suggesting other regulators may be at play in vivo for CCL11 and 
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CXCL10 (Figure 30A – 30C). 
Finally, using IFNγ-/- mice to model the effects of diminished CXCL9, we 
depleted NK cells in IFNγ-/- mice and examined eosinophilic accumulation in the heart on 
day 21. Similar to the CCR3-/- mice, IFNγ-/- mice still continued to accumulate 
significantly more eosinophils in the heart in the absence of NK cells (Figure 31A). From 
our data employing the CCR3–/– and IFNγ–/– models, we conclude that neither mechanism 
is sufficient to mediate NK-mediated control of eosinophil in isolation. Overall, these 
results demonstrate that there may be multiple redundant chemokines responsible for 
cardiac eosinophilic accumulation during EAM.   
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FIGURES AND TABLES 
Table 4. Diagnosis of Hypereosinophilic Syndrome (HES)201,203,207 
Condition 
1 Exclude patients with eosinophilia secondary to allergy, parasitic disease, 
infectious disease, and pulmonary diseases such as Loeffler’s or 
hypersensitivity pneumonitis 
2 Exclude patients with neoplastic disorders with secondary eosinophilia 
3 Exclude patients with neoplastic disorders involving eosinophils 
4 Exclude patients presenting with abnormal T-cell phenotypes 
CEL Conditions 1-4 have been met 
Myeloid compartment demonstrates clonal abnormalities 
Myeloblasts are > 2% in peripheral blood and between 5 and 19% in bone 
marrow 
HES Conditions 1-4 have been met and there are no myeloid abnormalities 
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A) Representative side scatter histograms of isotype and ASGM-1 antibody treated
animals at day 21. B) Representative Ly6G versus SiglecF bivariate plots at day 21 from 
viable CD45+ cells. C) Percentage of Ly6GloSiglecF+ eosinophils from cardiac CD45+ 
cells on D) day 14 (p=0.043) and E) day 21 (p<0.001) of EAM. Percentage of SiglecF-
Ly6Ghi neutrophils at F) day 14 (n.s.) and G) day 21 (n.s.). Significance calculated by 
unpaired t-test. 
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Figure 16. Increased eosinophils express high levels of MBP, SiglecF, and CD11b 
Rabbit IgG
ASGM-1
DAPI Major Basic Protein
A) Immunofluorescence staining of paraffin embedded cardiac sections from isotype
control and ASGM-1 treated mice on day 21 of EAM. Sections were stained with 1:500 
rat anti-MBP primary or rat IgG antibody, 1:200 anti-rat donkey PE-Texas Red antibody, 
and DAPI. Relative mean fluorescence intensity (MFI) of B) SiglecF (p<0.001) and C) 
CD11b (p<0.001) expression on Ly6GloSiglecF+ eosinophils from the heart and spleen of 
isotype control and ASGM-1 treated animals at day 21 of EAM by flow cytometry. 
Statistics calculated by unpaired t-test.  
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Figure 17. Eosinophils in the heart of ASGM-1 treated mice have an activated profile 
Levels of A) epx (p=0.05), B) prg2 (p=0.05), C) il1b 
(p=0.04), D) tgfb (n.s.), E) ccl11 (p=0.03), F) ccl24 
(n.s.), G) il4 (n.s.), H) il13 (n.s.), I) il6 (n.s.), and J) il10 
(n.s.) mRNA isolated from facs sorted Ly6GloSiglecFhi 
eosinophils from ASGM-1 treated mice at day 21 of 
EAM. Values shown as fold induction compared to 
spleen and controlled against HPRT levels. Significance 
calculated by student’s t-test.
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Figure 18. Mast cells, and mast cell mediators are not altered in the absence of NK cells 
A) FCεR1α+cKit+ mast cells (n.s.) as a percentage of total CD45+ cardiac cells at da 14 of
EAM in isotype and ASGM-1 treated WT animals. Relative mRNA levels of mast cell-
associated mediators B)IL33 (n.s.) and C) ST2 (n.s.) in total heart homogenates at day 14 
of EAM by qPCR normalized to levels of HPRT. D) FCεR1α+DX5+cKit- basophils 
(p=0.032) as a percentage of total CD45+ cardiac cells at day 14 of EAM in isotype 
control and ASGM-1 treated animals. Significance determined by unpaired t-test. 
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Figure 19. Myeloid populations are unaffected by NK depletion during EAM 
A) CD11b+ monocytes (n.s.) as a percentage of total CD45+ cardiac cells at day 14 of
EAM in isotype and ASGM-1 treated WT animals. B) Ly6Chi inflammatory (n.s.) and C) 
Ly6Clomid resident (n.s.) subsets as a percentage of total CD11b+ cardiac monocytes. D) 
CD11c+ dendritic cells (n.s.) as a percentage of total CD45+ cardiac cells at day 21 of 
EAM in isotype control and ASGM-1 treated animals. Significance determined by 
unpaired t-test. 
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Figure 20. B cell and T cell proportions are unaffected by NK depletion during EAM 
Lymphocyte percentages of A) B220+ B-cells (n.s.), B) CD3+ T cells (n.s.), C) CD3+CD4+ 
helper T cells (n.s.) and D) CD3+CD8+ cytotoxic T cells (n.s.) as a percentage of total 
CD45+ cardiac cells as a percentage of total CD45+ cardiac cells at day 21 of EAM in 
isotype control and ASGM-1 treated animals. Significance determined by unpaired t-test.  
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Figure 21. NK depletion increases Th2 and Th17 proportions at later stages of EAM 
T-cell subset examination by intracellular cytokine staining for A) IFNγ (Th1), B) IL13 
(Th2), and C) IL17A (Th17), as a proportion of cardiac CD3+CD4+ cells at day 14 (all 
n.s.) and day 21 of EAM following 4-6 hours of PMA and ionomycin stimulation with
Golgistop. Significance calculated by unpaired t-test. 
83 
Figure 22. Day 21 cardiac cytokine levels reflect changes in Th profiles 
Protein analysis of cardiac tissue by LINCO at day 21 of EAM in isotype control and 
ASGM-1 treated animals of A) IFNγ (n.s.), B) IL5 (p<0.001), C) IL13 (n.s.), D) IL17A 
(p=0.030), E) IL6 (p=0.030), F) IL12p40 (n.s.), and G) IL10 (n.s.). Significance 
determined by student’s t-test.   
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A) Percent of cardiac SiglecF+ eosinophils in WT and ΔdblGATA1 groups during EAM at
day 21 (ANOVA p<0.001) B) Histology scores of PBS, rabbit IgG, and ASGM-1 
antibody treated ΔdblGATA1 animals at day 21 of EAM (n.s.). C) Ejection fraction (n.s.) 
measured by echocardiography at day 21. D) Percentage of fibrosis (n.s.) as measured by 
Masson's Trichrome staining of cardiac sections at day 21. Significance by ordinary one-
way ANOVA with post-testing by Tukey’s multiple comparisons test. 
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T-cell subset examination by qPCR for A) IFNγ (Th1) (n.s.), B) IL4 (Th2) (p=0.004), C) 
IL6 (Th17) (p=0.052), and D) IL17A (Th17) (n.s.) mRNA in whole heart tissue 
homogenates normalized against HPRT mRNA levels and shown as a function of fold 
induction against isotype control levels. Significance calculated by unpaired t-test. 
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Levels of A) ccl11 (n.s.) and B) ccl24 (n.s.) mRNA at day 14 of EAM. C) CCL11 
(p=0.035) at day 21 of EAM. D) cxcl9 (p=0.004), and E) cxcl10 (p= 0.077) mRNA at day 
14 of EAM in ASGM1- and rabbit IgG-treated animals measured by qPCR of cardiac 
tissue. Significance calculated by unpaired t-test. 
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CFs were cultured with either IL4 or both IL4 and magnetically sorted NK cells (1:2 
ratio) for 94 hours. Levels of A) CCL11 (p<0.001), B) CXCL9 (p<0.001), C) CXCL10 
(p<0.001), D) CCL2 (p<0.001), E) CCL4 (p<0.001), F) CCL5 (p=0.002), G) CXCL1 
(p<0.001), and H) IL5 (p<0.001) protein in supernatant were measured by ELISA. 







Figure 27. NK cells alter levels of eosinophil-associated chemokines from CFs in vivo 
A) ccl11 (p=0.064) and B) ccl24 (p=0.020) mRNA were measured ex vivo by qPCR in
cardiac fibroblasts isolated at day 21 of disease. Significance calculated by unpaired t-
test.  
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A) Representative bivariate plots of Ly6G versus SiglecF CD45+-gated cells at day 21 of
EAM in isotype and ASGM-1 antibody treated eotaxin receptor (CCR3)-/- animals. B) 
Percentage of Ly6GloSiglecF+ eosinophils (p=0.001) from total cardiac CD45+ cells. 
Statistics calculated by unpaired t-test 
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Figure 29. NK cells mediate CCL11, CXCL9 and CXCL10 production from CFs via IFNγ 
in vitro  
A) CCL11 (p<0.001), B) CXCL9
(p<0.001) and C) CXCL10 (p<0.001) 
of in the supernatant of magnetically 
isolated NK cells cultured with either 
WT or IFNγRI-/- CFs for 96 hours as 
measured by ELISA. Significance of 
C-E by ordinary one-way ANOVA 
with post-testing by Tukey’s multiple 
comparisons test.  
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Figure 30. IFNγ controls CXCL9 levels during EAM 
A) CCL11 (p=0.798), B) CXCL9 (p=0.050)
and C) CXCL10 (p=0.369) protein levels at 
day 21 of EAM in the hearts WT and IFNγ-/- 
mice as measured by LINCO. Statistics 
calculated by unpaired t-tests.  
WT IFN -/-
1000












Figure 31. IFNγ is dispensable for NK-mediated control of eosinophil accumulation 
during EAM 
A) Percentage of Ly6GloSiglecF+ eosinophils (p=0.018) from total cardiac CD45+
cells at day 21 of EAM in isotype and ASGM-1 antibody treated IFNγ-/- animals.
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DISCUSSION 
The absence of NK cells from WT mice undergoing myocarditis lead to a specific 
and significant increase of in the proportion of eosinophils infiltrating the cardiac muscle. 
While WT isotype control animals had limited numbers of these cells averaging between 
0.5 – 2.0% of cardiac CD45+ cells, ASGM-1 treatment increased Ly6GloSiglecFhi
numbers ten-fold to approximately 10 – 15% of all infiltrating cells. We hypothesized 
that this increase in eosinophils was heavily involved in the increase of disease severity 
seen in the absence of NK cells, as eosinophils are known for their tissue damage 
potential and role in fibrosis. Furthermore, patients with necrotizing eosinophilic 
myocarditis have poor prognosis compared to other myocarditis subtypes, indicating that 
eosinophils are correlated with poor disease outcome in myocarditis.  
To determine if the eosinophils seen in the hearts of ASGM-1 animals had the 
potential for immune modulation and tissue damage, we profiled these cells by surface 
expression and mRNA levels for activation and maturation markers. Infiltrating 
eosinophils displayed an activated profile consistent with eosinophils isolated from lungs 
of mice infected with Nippostrongylus brasiliensis with upregulated SiglecF and 
CD11b237. As eosinophils aggressively participate in the clearance of N. brasiliensis 
infection, we postulate that similar profiles indicate activate immune modulation by 
eosinophils of their local environment. Also altered were mRNA levels of MBP and EPX, 
as mature and activated eosinophils contain granules that were formed during the 
maturation stages and no longer require synthesis of these proteins237.  
IL6, also upregulated in cardiac eosinophils, has been shown to be induced by 
IFNγ to co-localize to intercellular granules prior to secretion along with the granule 
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proteins238,239. Also increased were mRNA levels of TGFβ, mirroring the activated 
population seen in asthmatic airway inflammation models237,240. TGFβ also stimulates the 
development of fibrosis, which along with the deposition of MBP seen in ASGM-1 
treated hearts, might be responsible for increase of collagen in NK depleted mice241,242. 
Therefore, NK depletion likely has limited effects on eosinophils in the periphery, as 
cardiac eosinophils had distinctly different transcriptional profiles that those found in the 
spleen. 
Eosinophils have recently been shown to regulate muscle repair through the 
recruitment of fibroblast progenitors in striated muscle by IL4 and IL13187. It was 
possible that the increased fibrosis coinciding with the influx of eosinophils during EAM 
was due to dysregulation of this response mechanism after inflammation-mediated 
cardiac muscle damage. However, we saw no increase of IL4 and IL13 mRNA in cardiac 
eosinophils during EAM, signifying this is an unlikely mechanism. 
The increase of eosinophils in the heart during EAM in response to NK depletion 
in no way mirrors the huge influx of eosinophils seen in the tissue of patients with 
clinical eosinophilic myocarditis or in animal models of eosinophilic myocarditis. In 
those cases, dysregulation of eosinophils is likely due to more potent regulators of 
eosinophils, such as Th2-mediated mechanisms as demonstrated in IFNγ/IL17A-deficient 
mice with eosinophils comprising more than 30% of infiltrating cells after EAM 
induction. However, we show that even moderate increases in eosinophils can have 
significant effects on disease outcome. Therefore, the presence of eosinophils in EMB 
samples, even in moderate numbers, might be considered a risk factor for poor prognosis. 
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Furthermore, this data opens a new mechanism in the basic regulation of 
eosinophils. We indicate for the first time, the ability of NK cells in vivo to directly 
suppress eosinophils during inflammation. Th2-associated NK cells have previously been 
implicated asthma and allergy models to positive regulate eosinophil accumulation 
through the secretion of IL5. Here, we show that Th1-associated IFNγ producing NK 
cells can downregulate eosinophil infiltration through communications with cardiac 
resident cells. Our data support the concept of NK cells as a multifactorial cellular 
population comprised of heterogeneous and fluid subsets that are highly responsive to 
their local environment. However, it should be pointed out that NK cells are likely not 
required in the control of eosinophil trafficking and merely represent one of many 
mechanisms of regulation.  
An alternative hypothesis in the regulation of disease severity by NK cells 
involves alterations in monocyte populations. NK cells can induce macrophage and 
dendritic maturation and activation, leading to changes in antigen-specific T cell 
populations243. Furthermore, monocytes as the majority of the cells infiltrating the 
myocardium during EAM have been shown to influence myocarditis severity in 
EAM140,232.  
However, the increased disease severity in the absence of NK cells were not 
accompanied by changes in levels of CD11b-positive populations or expression of 
inflammatory monocyte marker Ly6C. Recently, we have published that monocyte 
control of inflammation in the heart was ultimately due to shifts in the Th cytokine 
secretion and cell populations, making monocytes the effector population36,140,141,244. 
Here, despite late changes in Th populations, no changes were observed in the monocyte 
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compartment, making the case that neither they nor Th2 and Th17 populations were 
responsible for increased disease severity.  
The lack of Th involvement as the ultimate mechanism of increased inflammation 
and collagen deposition in the absence of NK cells was emphasized by the continued 
increase of Th2 and Th17-associated cytokines in ΔdoubleGATA mice. NK depletion in 
ΔdoubleGATA resulted in increases in total cardiac IL4 and IL6, a surrogate for Th2 and 
Th17 populations. Despite this increase, no phenotypical changes in disease severity or 
collagen deposition were seen in the absence of eosinophils during EAM. Therefore, NK 
cells directly downregulate eosinophilic accumulation along with levels of Th2 and Th17 
populations. As the infiltrating cardiac NK cells were largely IFNγ producing, this is 
consistent with the reported ability of NK cells to downregulate Th2 and Th17 responses 
through inhibition of anti-specific T cells expressing Rorγt and GATA3245,246.  
We did note limited decreases of basophils due to ASGM-1 treatment 
corresponding with reports in literature127. We expect that this diminution has limited 
effect as proportions of Th2 cells were elevated after ASGM-1 antibody treatment, the 
opposite of what would be expected if basophils were involved mechanistically.1 Mast 
cells, also implicated in the control of eosinophils in myocarditis, were not different 
proportionally in the absence of NK cells and likely were not the major regulator of 
eosinophil infiltration. This was supported by unchanged levels of IL33 and ST2, 
associated with mast cell activation and ILC2 proliferations. Other than eosinophils, the 
alterations in basophils were the only significant difference in cardiac infiltrating 
populations during EAM after NK cell depletion.   
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We hypothesized that NK cells mediated eosinophilic accumulation in EAM 
through cardiac resident cells, as our lab recently determined that CFs are a primary 
mediator in IL17A-mediated EAM232. Furthermore, NK cell and fibroblast interactions 
have been well-established. Tumor fibroblasts can interfere with NK cytokine production 
and cytoxicity via PGE2.247 and synoviocytes in RA can express NK-receptor ligands that 
result in NK activation by direct contact.248 Also, there has been increasing awareness 
that resident cells play a large role in the determination of cardiac fate during 
inflammation.249.  
In our non-exclusive list of chemokines analyzed, both positive and negative 
mediators of eosinophils were shifted towards a pro-eosinophilic environment in the 
absence of NK cells. Consistent with our reports of CFs as major mediators of disease, 
our results demonstrate that NK cells alter eosinophilic chemokine expression in vivo, in 
vitro, and ex vivo from CFs. Of these, eotaxins, major controllers of eosinophilic 
trafficking in asthma and allergy, were the most dysregulated250-253. However, 
chemokines are notorious for functional redundancy and it is difficult to obtain 
phenotypic evidence for their role in disease254,255. This was supported in EAM by the 
failure of CCR3-/- and IFNγ-/- mice to show any changes in eosinophilic accumulation in 
the absence of NK cells.  
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CHAPTER V: CONCLUSION 
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Conclusions 
In this study, we demonstrated that the protective qualities of NK cells extend well 
beyond viral inhibition in myocarditis. By depleting NK cells, but not NKT cells, using 
treatment with ASGM-1 antibodies, we found that NK cells directly downregulated 
cardiac inflammation and collagen deposition during EAM, a pathogen-free model of 
autoimmune myocarditis, by limiting cardiac eosinophil accumulation though 
interactions with cardiac resident cells (Figure 4).  
These data opens the possibility for using NK cells or their products as a biologic 
therapy for myocarditis. Developments in the treatment for clinical myocarditis is 
constricted by the opposing needs in the viral and autoimmune components of disease. 
Ideally, an intervention could be designed that would target both needs simultaneously. 
Our lab has now shown that NK cells are clearly protective in both viral and 
autoimmune-mediated driven forms of myocarditis. NK-related therapies are an area of 




Like in all scientific research, the work begun in this dissertation is far from 
complete. While we were able to clearly define a protective role for NK cells in the 
pathogenesis of myocarditis and deposition of collagen in the heart, we only showed 
circumstantial evidence for the specific mechanisms by which NK cells control 
eosinophilic accumulation. The removal of specific trafficking mediators CCR3 and IFNγ 
did not restore eosinophils to isotype control levels when NK cells were depleted, 
signifying our inability to provide hard evidence for the regulation of eosinophils through 
chemokines. Part of this failure is inherent to the redundant nature of chemokines.  
The depletion of NK cells using ASGM-1 is also less than ideal. While we did 
show that no major alterations in other cell populations occurred, with the exception of 
basophils, it would be better to confirm these results in an genetically specific NK-
deficient BALB/c model, which currently does not exist. 
Two major foci remain in the future directions of this research. Firstly, while we 
investigated the ability of NK cells to modulate disease through resident cells, we did not 
explore the ability of NK cells to directly interact with eosinophils. In order to do this, we 
are currently pursuing co-culture experiments between naïve splenic NK cells and mature 
eosinophils isolated from the blood of IL-5 transgenic animals. As reviewed in the 
introduction to Chapter III, NK cells have been recently implicated in the activation and 
subsequent apoptosis of eosinophils in vitro. After co-culture, eosinophils will be 
examined for annexin V and Live/Dead staining in order to determine if the presence of 
NK cells resulted in increased apoptosis. If this is indicated in the results, it is possible 
that NK cells in the cardiac environment may directly control eosinophil accumulation by 
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cell-mediated apoptosis. 
Lastly, the pressing question of the role of eosinophils in the pathogenesis of 
myocarditis and DCMI itself remains. We showed that influx of eosinophils in the heart 
resulted in overall increased inflammation and collagen deposition, possibly linked to 
increased TGFβ and IL6 secretion and the deposition of MBP in the tissue, but the 
specifics of eosinophil-mediated damage are unknown in EAM. Certainly, the model of 
NK depletion in EAM provides a tantalizing glimpse of what pathogenic role eosinophils 
may play in the heart. Ultimately however, depletion of NK cells only resulted in at most 
10% of the cardiac infiltrate being eosinophilic, and thus cannot be considered a model of 
clinical eosinophilic myocarditis, where the vast majority of cells are eosinophils. We are 
currently exploring models of eosinophilic myocarditis, either through the use of IL5-
transgenic mice or through Th2 deviated myocarditis model that are deficient in both 
IL17A and IFNγ224.  
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Figures and Tables 
Figure 32. Summary of dissertation 
Activated NK cells accumulate in the heart during EAM and suppress 
eosinophilic infiltration through mechanisms that may involve the expression of 
chemokines from cardiac resident cells. The release of MBP, TGFβ, and IL6 from the 
infiltrating eosinophils into the cardiac environment may be responsible for the resulting 
increase in cardiac inflammation and fibrosis seen in the absence of NK cells. NK and 
cardiac fibroblasts interactions in vitro led to the release of IFNy from NK cells in a cell 
contact-dependent manner. This IFNγ directly modulated the expression of CCL11, 
CCL24, CXCL9, and CXCL10, chemokines that have direct trafficking effects on 
eosinophils. Therefore, NK cells may control eosinophil infiltration directly or indirectly 
through resident cell mediators.  
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Thesis Work 
Natural killer (NK) cells control cardiac eosinophilia in experimental autoimmune myocarditis (EAM) 
Explores the protective role of NK cells in EAM. Determined that the increased cardiac inflammation, fibrosis, 
and cardiac dysfunction upon depletion of NK cells in wildtype mice undergoing EAM is directly mediated by 
increased eosinophil accumulation in the heart due to global changes in both Th profiles and eosinophil-related 
chemokine production by cardiac resident cells both in vitro and in vivo.  
The autoimmune regulator gene (AIRE) is required for peripheral Th17 responses 
Examines the mechanism behind spontaneous candidiasis in clinical patients with genetic defects in the AIRE 
gene by determining whether Th17 cytokines are AIRE-dependent antigens. Used clonal expansion and single 
cell sequencing techniques to examine the sequence of T-cell receptors in CD3+CD4+ cells to identify T-cells 
reactive against Th17 cytokines.  
Relevant Work Experience 
2008-2009 Emerging Infectious Disease Fellow 
Department of Parasitic Disease, Centers for Disease Control and Prevention 
Atlanta, Georgia 
Principal Investigator: W. Evan Secor 
Project: Increased SHIV susceptibility in rhesus macaques infected with schistosomasis 
Grants and Fellowships 
2011-2015 Ruth L. Kirschstein National Research Service Award (NIH) 
F31 HL112665-01A1: Role of natural killer cells in myocarditis 
Principal Investigator: SuFey Ong 
2010-2011 Otis and Calista Causey Fellow of Immunology 
2008-2009 Emerging Infectious Disease Fellowship, American Public Health Laboratories 
Publications 
Under revision for Circulation Research: Ong S, Ligons DL, Barin JG, Wu L, Talor MV, Diny N, Fontes JA, 
Gebremariam E, Kass DA, Rose NR, Cihakova D. Natural killer cells suppress cardiac inflammation and 
fibrosis by regulating eosinophilic infiltration.  
Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, Bedja D, Zhang H, Sheikh A, Margolick JB, 
Iwakura Y, Rose NR, Cihakova D. (2014) Cardiac fibroblasts mediate IL17A-driven inflammatory dilated 
cardiomyopathy. Journal of Experimental Medicine. 2014 Jun 16. Epub ahead of print. 
Barin JG, Baldeviano GC, Talor MV, Wu L, Ong S, Fairweather D, Bedja D, Stickel NR, Fontes JA, 
Cardamone AB, Zheng D, Gabrielson KL, Rose NR, Cihakova D. (2013). Fatal Eosinophilic Myocarditis 
Develops in the Absence of IFN-γ and IL-17A. The Journal of Immunology, 191(8), 4038-4047. 
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Cihakova D. (2012) Macrophages participate in IL17A-mediated inflammation. European Journal of 
Immunology, 42(3):726-36 
Poster Presentations and Scientific Abstracts 
Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Zhang H ,et al. (2013, August). IL-17A Gives Rise to 
Proinflammatory and Profibrotic Monocytes by Inducing GM-CSF Production from Cardiac Fibroblasts. In 
Association of Medical Laboratory Immunologists Annual Meeting. Savannah, Georgia. 
Ong, S., Ligons, D., Baldeviano, C., Barin, J., Talor, M., Wu, L. et al (2013, June). Natural killer cells suppress 
cardiac eosinophilia in autoimmune myocarditis. In Cold Spring Harbor Laboratories. 78th Symposium on 
Immunity and Tolerance. CSHL, New York.  
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Ong, S., Ligons, D., Baldeviano, C., Barin, J., Talor, M., Wu, L. et al (2013, April). Natural killer cells suppress 
cardiac eosinophilia in autoimmune myocarditis. In Young Investigator’s Day, Department of Pathology at 
Johns Hopkins Medical Institution. Baltimore, Maryland.  
Legault, J. A., Baldeviano, G. C., Ong, S., Wu, L., Barin, J. G., Talor, M. V. et al (2013). 161: IL6 promotes the 
progression of experimental autoimmune myocarditis to dilated cardiomyopathy. Cytokine, 63(3), 281. San 
Francisco, California.  
Barin, J., Baldeviano, G., Talor, M., Wu, L., Ong, S., Fairweather, D. et al (2013, May). IL17A and IFN gamma 
jointly control rapidly fatal eosinophilic myocarditis in mice. In JOURNAL OF IMMUNOLOGY (Vol. 190). 
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ROCKVILLE PIKE, BETHESDA, MD 20814 USA: AMER ASSOC IMMUNOLOGISTS. 
Legault, J., Baldeviano, G., Barin, J., Wu, L., Ong, S., Talor, et al (2012, May). IL6 is necessary for the 
progression of experimental autoimmune myocarditis to dilated cardiomyopathy. In JOURNAL OF 
IMMUNOLOGY (Vol. 188). 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA: AMER ASSOC 
IMMUNOLOGISTS. 
Baldeviano, G., Barin, J., Wu, L., Talor, M., Ferrer, P., Chen, P, Legault J., Ong S., et al. (2011). Eosinophils 
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IMMUNOLOGISTS. 
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Teaching Experience 
2010-2013  Teaching Assistant 
Public Health Biology, Johns Hopkins School of Public Health  
Graduate level class for incoming MPH students comprising of MD and PhD holders. 
Led student and faculty discussions, graded exams and homework, and answered student 
questions regarding coursework and logistics.  
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Skills and Techniques 
12+ color flow cytometry analysis 
Advanced and basic mouse skills  
Basic histopathology skills 
CFA-driven immunization models 
ELISA 
Grant writing (NIH, AHA, etc.) 
Immunofluorescent microscopy 
Primary cell isolation and culture 
qPCR and RT-PCR 
Single cell TCR sequencing 
